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Improving patient outcomes in chronic disease is of critical importance to the future
of health care. Gout, affecting 4% of the US population, is a highly treatable chronic
disease from which patients experience unnecessarily suboptimal outcomes. In this
dissertation, I demonstrate how interrelated patient and provider factors affect patient
outcomes in gout. First, I describe how only 14% of gout patients know their serum urate
(SU) goal for urate lowering therapy (ULT) despite otherwise being knowledgeable about
gout and its treatment. I then demonstrate the importance of multiple patient and
provider factors in achieving SU goal. Specifically, I demonstrate that ULT medication
adherence, ULT dose escalation and a high ULT starting dose are associated with SU
goal attainment. However, I show that a high starting dose is also associated with worse
SU goal attainment through its negative impact on medication adherence. These
findings demonstrate not only the importance of patient and provider behaviors in
achieving optimal outcomes, but also their interrelated nature. Finally, I report that there
is no evidence from a large national study that ULT dose escalation reduces mortality
among gout patients. In further analysis, I demonstrate that the lack of evidence could
be due to inadequate final ULT doses observed even among patients receiving dose
escalation. Importantly, the patient and provider factors I identify in this work are all
modifiable. Future interventions should address the broad care context outlined in the
Chronic Care Model to target these interrelated, modifiable factors and achieve optimal
outcomes in gout.
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Chapter 1:

Introduction

1.1 Chronic Illness and Care
Chronic illness has become the single greatest contributor to decreases in
individuals’ quality of life and has also begun to drive health care cost.1-3 In the United
States (US), approximately half of all adults have one or more chronic illnesses and half
of those have at least 2 chronic illnesses.4 Chronic illnesses such as asthma, diabetes
and gout can lead to substantial activity limitations and loss of quality of life.5-7 Care for
patients with one or more chronic illnesses now accounts for over 85% of health care
spending today.3 Yet, despite the ubiquitous and increasing impact of chronic illness,
patients and the health care system struggle to achieve optimal, but attainable,
outcomes.2,8
In 1996, Wagner et al. created one of the first models for understanding and
improving chronic illness care: the Chronic Care Model (CCM).9 The model was
developed in response to growing recognition that patients, health care providers and
the health care system are too often ill-prepared to address chronic care needs. Patients
with one or more chronic illnesses must often engage in more extensive and long-lasting
self-management activities than patients with acute illnesses.10 Yet, many patients
burdened by chronic illness are not aware of or prepared for the self-management
necessary to achieve desired results.11,12 Similarly, there is evidence that health care
providers deviate from the best practices necessary to support patients with chronic
illness in achieving optimal outcomes. More broadly, there is evidence from a systematic
review of health systems’ chronic care improvement initiatives that broader contextual
factors affect chronic illness care outcomes.13 Wagner and colleagues assembled this
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evidence into the CCM in order to depict relevant domains that need to be targeted to
improve chronic illness care and outcomes.
Over time, the CCM framework (Figure 1) developed to reflect how chronic care
occurs in 3 overlapping environments: the community, the health care system and the
health care provider’s organization.14 Within these environments, CCM identifies 6 areas
where targeted efforts affect outcomes: community resources and policies, selfmanagement support, delivery system design, decision support, clinical information
systems and the organization of health care. Each of these areas contributes to patient
outcomes in unique ways, but ultimately facilitate “an informed, activated patient
interacting with a prepared, proactive practice team” to produce “high-quality, satisfying
encounters and improved outcomes.”14
In chronic care, CCM recognizes that patients become their own primary caregiver.10
They are, therefore, required to have a broad range of self-management skills in
problem solving and resource utilization.12 Patients with these skills tend to achieve
better outcomes.15,16 Health care providers, by contrast, provide medical insight,
encourage development of problem-solving skills, and help access resources over
time.10 If health care providers are well prepared, knowledgeable, and proactive about
specific chronic care needs, patients are more likely to experience improved outcomes.
The model suggests that patients and providers together, through productive interactions
related to their roles, may achieve optimal care outcomes.17
Using CCM as a framework, barriers to optimal outcomes for specific diseases can
be better identified and understood. In the following section, I use the CCM as a
framework for understanding evidence of suboptimal outcomes in gout with particular
attention to the interrelated roles of patients and health care providers.
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Figure 1 Chronic Care Model
The Chronic Care Model (CCM) places emphasis on productive interactions between an informed, activated patient and a prepared, proactive health care team.
These interactions occur within the context of 3 overlapping environments: the community, health systems and provider organizations. Within these environments,
the model identifies 6 essential areas that together affect how patients and providers interact to improve outcomes in chronic disease care. Adapted with
permission from work by Wagner and colleagues at the MacColl Center for Health Care Innovation. 18 Copyright 1996-2015 The American College of Physicians.
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1.2 Gout and Gout Management
Gout is the most common inflammatory arthritis in the US with a prevalence that
has increased in recent decades to nearly 4%.19,20 Resulting from sustained
hyperuricemia, gout can have a considerable, negative impact on individuals’ quality of
life leading to increased work absenteeism,21 disability,22-24 and health care utilization.2527

Furthermore, gout and hyperuricemia may be related to an increased risk of

mortality.28-31 Yet, despite the substantial prevalence and health impact of gout, and the
availability of highly effective management strategies, suboptimal patient outcomes
remain all too common.32,33
As with any chronic disease, achievable outcomes in gout are partially a function
of the disease process itself as well as available treatments. Gout has a well-defined
disease pathogenesis.34 It is characterized by intermittent, extremely painful bouts of
arthritis called attacks or flares.35 These attacks are induced by the presence of
monosodium urate (MSU) crystals in synovial joints and surrounding tissues secondary
to persistent hyperuricemia. Attacks typically last 5 to 12 days without treatment36 and
are followed by periods of disease quiescence, often termed intercritical gout.35
Untreated, the attack frequency increases alongside the body’s total MSU crystal burden
until a persistent arthritis develops, a severe form of gout characterized by the
subcutaneous deposition of MSU termed tophi.34 Treated properly, however, a diagnosis
of gout does not need to result in intractable future gout attacks.
Medical treatment of gout is commonly divided into two parts: short-term alleviation
of the pain and inflammation from the attack37 and long-term urate lowering therapy
(ULT) to reduce MSU crystal burden.38 For short-term therapy targeting attacks, the
most common therapies used are anti-inflammatory doses of non-steroidal antiinflammatory drugs (NSAIDs), colchicine, and/or glucocorticoids. For long-term therapy,
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xanthine oxidase inhibitors (XOI) are considered first-line therapy and are the most
commonly prescribed ULT.38 Numerous studies have shown that patients on XOIs,
especially those achieving and maintaining a serum urate (SU) concentration < 6.0
mg/dl,39 experience reduced tophi size, frequency of flares, and pain.40-42 The reduction
in MSU crystals resulting from ULT and cessation of gout attacks can be so dramatic
after long-term maintenance below SU goal that “cure” is not an uncommon outcome
described in the literature.43,44 However, most patients never achieve SU goal and are
thus likely continue to experience gout attacks.32
The CCM suggests a framework for achieving optimal outcomes such as SU goal
and elimination of future gout attacks.14 For a chronic disease like gout, the model
emphasizes the role of a proactive health care team and an informed, active patient. The
model then places the provider and patient in a broader context composed of 6 essential
areas. While I return in Chapter 5 to the importance of these 6 areas for the future of
gout care, this dissertation first investigates the role of provider and patient behaviors in
achieving optimal outcomes.
From the provider perspective, there is myriad evidence demonstrating that gout
care is suboptimal. For instance, health care providers may perform suboptimally
according to both quality indicators and safe prescribing benchmarks.45-48 Recognition of
these potential issues, in part, prompted the development of evidence- and consensus
based guidelines by multiple international groups.37,38,49,50 Since publication of those
guidelines, studies have consistently demonstrated that provider practices remain
suboptimal.32,33,48,51 For instance, the 2012 American College of Rheumatology (ACR)
gout management guidelines suggest that health care providers start gout patients on a
low ULT dose (e.g. allopurinol ≤ 100 mg/day) followed by gradual dose escalation until
SU is < 6.0 mg/dl.38 Yet, only one in four patients have SU assessments within 6 months
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of ULT initiation and less than one-third ever undergo ULT dose escalation.32 While
there have been widespread reports of suboptimal care, there is currently limited
knowledge regarding which provider behaviors affect attainment of optimal outcomes in
gout such as SU goal < 6.0 mg/dl.32,52
From the patient perspective, long-term self-management of gout consists
primarily of understanding the disease and its treatment, properly taking ULT, and
avoiding life-style risk factors.38Like providers, there is evidence that patients struggle in
their chronic care role. There are qualitative reports that patients lack understanding of
gout and its treatment.53-55 Medication nonadherence has been well described in gout
with approximately 6 out of every 10 patients being considered nonadherent to
prescribed ULT.32,56 However, few studies connect any specific patient behaviors,
including ULT adherence to achieving the optimal outcome of SU goal attainment in
gout.32,52 Further work is needed to demonstrate that this association is independent of
the many other healthful behaviors in which adherent patients often simultaneously
engage.57
Taken together, there is burgeoning evidence that patient and provider behaviors
are suboptimal in gout, but limited evidence connecting these behaviors to important
outcomes. Furthermore, no studies have investigated how these behaviors may relate
through potential causal pathways. Further work demonstrating the interrelation of
patient and provider factors with outcomes could inform future interventions using the
CCM framework to improve outcomes in gout.

1.3 Dissertation Objectives and Contributions
The objective of this dissertation is to develop a model of modifiable patient and
provider factors associated with optimal outcomes in gout. In Chapter 2, I describe
patients’ gout-specific knowledge, including a lack of knowledge regarding an important
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therapeutic goal, and the opportunity that this gap in knowledge represents for a goaloriented care approach. In Chapter 3, I develop a more comprehensive model to test the
hypothesis that certain interrelated patient and provider factors are associated with SU
goal attainment, including some factors that appear to indirectly impact this outcome
through medication adherence. In Chapter 4, I demonstrate the potential importance of
these patient and provider behaviors by testing the hypothesis that one provider factor,
appropriate ULT dose escalation, is associated with decreased mortality among gout
patients. Finally, in Chapter 5, I discuss how the work presented in this dissertation
contributes to our understanding of how to improve gout care within the context provided
by the CCM framework.

Chapter 2:
Target Serum Urate: Do Gout Patients
Know Their Goal?
2.1 Background
Self-management is recognized as an important driver of outcomes in chronic
diseases, including gout. Treatment goals provide focus for self-management activities
and promote integration of valuable feedback for patients regarding their progress.58,59 A
treat-to-target serum urate (SU) strategy for gout patients with an indication for urate
lowering therapy (ULT) has been widely endorsed as a means of optimizing clinical
outcomes. Achievement of a SU < 6 mg/dL has been associated with improved
outcomes, including reductions in gout flare frequency and tophi.39-42,60,61 Thus, multiple
international guidelines support the adoption of such a treatment target.38,49,50,62 The
target is intended to guide health care providers’ care, but it also represents a critical
domain of patients’ gout-specific knowledge. The European League Against
Rheumatism (EULAR) reported “that [patient] education on gout and its treatment
improves outcome[s].”49 The recently published American College of Rheumatology
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(ACR) guidelines were more explicit in recommending that patients understand the role
of uric acid as “the key long-term treatment target.”38
Although substantial attention in gout has been given to suboptimal adherence to
quality of care indicators among providers45-47 and low SU goal attainment among
patients,32,48 it is largely unknown to what extent patients understand gout and their
treatment. Patients report that they are concerned, but uninformed about whether or not
ULT triggers gout attacks,55 a well-recognized event complicating such treatment. Other
patients lack familiarity with ULT as a treatment option and do not appear to understand
its role in gout management.54 Furthermore, patients who believe they have little control
over their gout or believe that treatment does not help control their gout experience
worse musculoskeletal disability over time.53 The low level of confidence and disease
knowledge reported by patients stands in stark contrast to the robust evidence
supporting the efficacy of ULT.40-42
Many gout educational materials (>50%) fail to address SU goal attainment.63 It
remains largely unknown whether patients understand the role that uric acid plays in
gout and the importance of SU goal attainment in chronic disease management. The
objective of the present study was to examine gout patients’ knowledge of their
condition, including the central role of achieving and maintaining SU goal with the use of
ULT. Furthermore, I examined, for the first time, factors associated with SU goal
knowledge and whether having this knowledge is associated with select health
outcomes.

2.2 Methods
Design and Setting
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This was a cross-sectional study to determine levels of gout-specific knowledge and
factors associated with gout-specific knowledge among a population of gout patients at a
single Midwestern Veterans Affairs (VA) medical center. The study was approved by the
local VA Institutional Review Board.
Sample and Procedures
Patients were 19 years or older with at least one gout International Classification of
Diseases (ICD)-9 code (274.XX), excluding gouty nephropathy (274.19, 274.10), and
filled at least one allopurinol prescription between August 1, 2011 and July 31, 2012
(“enrollment allopurinol”). Most patients’ first allopurinol was prescribed prior to the
enrollment allopurinol meaning that a majority of identified patients were prevalent
allopurinol users. A total of 1,553 patients met inclusion criteria (Figure 2). Patients were
excluded if they were deceased or had one of four conditions, each recognized as a
potential alternative indication for allopurinol as recorded by ICD-9 codes: a history of
hematologic malignancy, tumor lysis syndrome, stage 5 chronic kidney disease (CKD) or
nephrolithiasis.
A total of 1,437 patients, representing all remaining eligible patients, were mailed a
recruitment letter and questionnaire in February 2014. A repeat mailing occurred 6
weeks following the initial mailing for non-responders with responses accepted until May
2014 similar to the Dillman method.64 The questionnaire included 43 questions used to
collect socio-demographics, patient activation, health outcomes, gout knowledge, and
patients’ treatment plan confidence.
Linking responses to administrative data, I reapplied exclusion criteria using
laboratory proxies for tumor lysis syndrome (SU > 6 standard deviations above the
mean) and CKD stage 5 (estimated glomerular filtration rate (GFR) < 15 ml/min). I
required patients to have a pre-enrollment period of at least 6 months of observation with
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no allopurinol prescription prior to their first ever allopurinol prescription on record. To
determine the 6 month period, I assessed the patient’s first observable event in the VA
defined as the first clinic visit or pharmacy prescription fill. If the patients’ first observable
event was greater than 6 months prior to the first allopurinol fill, then they were included
in the study. This reduced potential misclassification of allopurinol starting dose and
dose escalation as well as anti-inflammatory prophylaxis. Application of these final
criteria excluded 274 individuals who had returned their questionnaires.
Questionnaire. The questionnaire was composed of 43 questions, including the
following: sociodemographics, a modified version of a gout-specific knowledge
questionnaire,65,66 the Patient Activation Measure (PAMTM),67,68 and self-reported health
outcomes. The gout-specific knowledge section was adapted from a longer
questionnaire resulting in 6 multiple-choice questions as summarized in Table 1. All
questions had 1 correct answer among 5 options with “Don’t know” as a possible option
for each question. Missing answers were coded as “Don’t know.” The gout-specific
knowledge section of the questionnaire had an excellent response rate with only 0.8 to
2.9% missing data for any question and 98.4% of respondents missing responses for 1
or fewer questions out of 6.
The PAMTM is used to quantify a patient’s engagement in their own care regardless
of the specific condition they have. It is designed to assess a person’s self-perceived
knowledge, skills and confidence related to managing their health and health care on a
unidimensional, developmental scale from the least activated at 0 to the most activated
at 100.67,68 The most recent version includes 13 questions with strong psychometric
properties that can categorize patients into 4 levels (1-4), where 1 is least activated and
4 is most activated.68 Patients in level 1 tend to be passive partners in their own health
care and view their health provider as being in charge, whereas patients at level 4
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actively adopt healthful behaviors and see themselves as their own primary health
advocate. The PAM was scored according to Insignia Health recommendations.69
For self-reported health outcomes, patients were asked to report the number of gout
flares they had in the past 6 months and rate their current overall health and goutspecific health on a visual analog scale (0 to 10 cm). For health-related quality of life, all
patients completed the EQ-5D-5L.70
Electronic Records. Clinical VA laboratory data were a source of many study
measures including the determination of whether patients ever achieved SU goal after
ULT initiation (< 6.0 mg/dL). ICD-9 codes were used to determine each patient’s
comorbidity burden as measured by the Rheumatic Disease Comorbidity Index
(RDCI).71,72 Each patient’s most recent GFR (ml/min/1.73 m2) and body mass index
(BMI, kg/m2) were abstracted. The proportion of days covered (PDC) was used to
determine medication adherence from prescription dispensing data. The PDC is defined
as the number of days the patient has medication available out of the total days of
observation (days with medication available/days of observation) after adjusting for early
refills and truncating at the end of observation. It is endorsed by the Pharmacy Quality
Alliance as the preferred method for quantifying medication adherence using pharmacy
claims data.73 For this study, the PDC was calculated during a fixed, 360-day period
initiating on the day of the patient’s first allopurinol prescription after August 1, 2011.
This provided a fixed time period of sufficient length for medication adherence
observation nearest the time of questionnaire completion. National Provider Identifier
and Drug Enforcement Administration numbers as well as VA clinic codes were used to
determine providers and clinical specialties associated with each gout diagnosis and
allopurinol prescription. Treatment duration was defined as the number of years between
first allopurinol prescription and final on record. Finally, dose escalation was defined as
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an increase in the dose of allopurinol from the first dose in the record to the final dose
without regard to intervening doses, also consistent with previous literature.32
Statistical Analysis. Demographic and questionnaire data were analyzed using
descriptive statistics. Internal consistency for the gout-specific knowledge questions was
assessed using Cronbach’s Alpha. Chi-squared, Wilcoxon rank-sum and t-tests were
used to determine factors associated with SU goal knowledge. Multivariable logistic
regression with backwards stepwise selection, beginning with factors significant at an
alpha ≤ 0.2 level in bivariate analyses, was used to determine independent associations
with SU goal knowledge. Two sensitivity analyses were done requiring patients to have 2
or more gout diagnostic codes separated by 30 days or more (n = 69 excluded) and
requiring 12 or more months of prior observation (n = 54 excluded). Given the limited
number of patients demonstrating this knowledge and the number of possible health
outcomes examined, associations of SU goal knowledge with gout outcomes were
examined in unadjusted exploratory analyses without statistical correction for multiple
comparisons. Considering the number of SU tests following the first ULT on record, the
count was modeled using a generalized linear model assuming a negative binomial
distribution to account for over-dispersion and a log link. All analyses were done in SAS
version 9.4 (SAS Institute, Cary, NC).
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Figure 2 Study Flow Diagram
Study personnel began with a list of 1553 patients already excluding those patients with ICD-9 codes for
tumor lysis syndrome, stage 5 chronic kidney disease (CKD), gouty nephropathy or nephrolithiasis.
Separate lists of recently deceased patients (n = 54) and patients with a history of cancer (n = 28) who met
study inclusion criteria were provided, but subsequently excluded. Prior to the first questionnaire mailing, 34
patients elected to opt out upon receiving the recruitment letter. From the mailing, 100 more opted out, were
learned to be deceased or had no forwarding address. Overall, the questionnaire had a 62% response rate
(886/1437). Using laboratory proxies, the tumor lysis syndrome and CKD stage 5 exclusion criteria were
reapplied. Additionally, a 6-month allopurinol-free pre-enrollment period of observation was required. The
final analysis cohort was 612 patients.
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2.3 Results
Of the original 1,437 patients mailed a questionnaire, 886 (62%) returned their
questionnaires. After exclusion criteria were reapplied, the overall cohort size was 612
patients whose primary indication for allopurinol was gout and who had at least 6 months
of prior observation before receiving their first allopurinol prescription. Questionnaire
responders were similar to non-responders in age (72.1 years vs. 72.8 years, p = 0.36),
proportion that were male (98.2% vs. 99.2%, p=0.15), BMI (32.4 kg/m2 vs. 32.0 kg/m2, p
= 0.41), comorbidity burden (RDCI 2.8 vs. 3.0, p=0.12), treatment duration (5.9 years vs.
6.2 years, p = 0.59) and GFR (65.5 mL/min vs. 65.5 mL/min, p = 0.99) (Table 2). In
contrast, questionnaire responders were more likely than non-responders to have
received their first prescription for allopurinol in a rheumatology office vs. primary care or
other (6.9% vs. 2.0%, p < 0.001) and were more adherent to allopurinol (PDC median
0.94 vs. 0.91, p = 0.005). Questionnaire responders were also more likely than nonresponders to have had a SU level checked within the first 2 years after ULT initiation
(66.0% vs. 52.9%, p < 0.001).
Among questionnaire responders, the mean age of first gout attack was 51.6 years,
a majority self-reported Caucasian race (89%), and had at least a high school graduate
level of education (89%). Using allopurinol prescription fill data, I determined that
questionnaire responders received care from a large number of health care providers (n
= 405), but that 49 providers (12%) were responsible for 74% of the filled allopurinol
prescriptions. A similar distribution was observed when using ICD-9 codes. Providers
from two clinics accounted for 91% of prescription fills (89% from primary care and 2%
from rheumatology). Rheumatologists were involved at any time in prescribing
allopurinol for 74 (12%) of the 612 gout patients.
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The proportion of gout patients answering correctly was high for all knowledge
questions except SU goal (Table 1). For the 5 questions other than SU goal, 72% of
respondents answered correctly on 4 or more questions. By comparison, only 14% knew
their SU goal. The vast majority (78%) of responders chose “Don’t know” for the SU goal
question compared to only 6 to 35% choosing “Don’t know” for any other question. The
six-question gout-specific knowledge section had acceptable internal consistency (0.61)
with the SU goal question and was slightly improved without it (0.64).
A variety of demographics, baseline health behaviors and health process factors
were associated with SU goal knowledge in bivariate and logistic regression analyses
(Table 3). In unadjusted analyses, patients demonstrating SU goal knowledge were
younger, had a lower comorbidity burden, were more activated as measured by the
PAM, were more likely to get all other gout-specific knowledge questions correct, be
treated by a rheumatologist and have their ULT dose escalated during observation. In
multivariable logistic regression, patients with rheumatologists as the initial prescriber
had 3.0 times the odds of knowing their SU goal as patients with other types of providers
(95% CI 1.4 to 6.2). Patients with 1-point higher RDCI had 17% lower odds of knowing
their SU goal (95% CI 0.70 to 0.98). As might be expected, patients who knew the other
5 gout-specific questions had 2.1 times the odds of knowing their SU goal compared to
patients who correctly answered 4 or fewer questions (95% CI 1.3 to 3.4). Because
some patients may interact with rheumatologists later in their care, I also considered
whether patients had ever been prescribed allopurinol by a rheumatologist. The adjusted
odds ratio for this association increased to 3.8 (95% CI 2.1-6.9) while the estimates for
RDCI and High Gout Knowledge remained stable (data not shown).
In exploratory analysis considering major health outcomes (Table 4), SU goal
knowledge was not associated with the EQ-5D-5L health utility index (p = 0.45), gout
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specific health (p = 0.72) or SU goal attainment < 6.0 mg/dL (p = 0.44). However, gout
patients with SU goal knowledge reported slightly better overall health on an 11-point
VAS compared to patients without that knowledge (8 vs. 7, p = 0.04). Additionally, there
was a trend, though not statistically significant, toward patients with SU goal knowledge
having more attacks within the past 6 months. SU goal knowledge was associated with
an increase in SU tests during 1- and 2-year periods following ULT initiation after
controlling for whether a rheumatologist was the initial prescriber. During the first year of
therapy, SU goal knowledge was associated with 45% (95% CI 1.10 to 1.92) more SU
laboratory tests. Extending to a 2-year follow-up, SU goal knowledge was associated
with 56% (95% CI 1.23 to 1.97) more SU laboratory tests.
In sensitivity analyses, limited to patients with at least two diagnostic gout codes or
with at least 12 months of prior observation, similar results were observed with respect
to the proportion of patients demonstrating SU goal knowledge and its associations with
potential predictors and health outcomes (data not shown).

17

Table 1 Gout-specific Knowledge Questionnaire

n=612 (%)
1. What is the ideal blood uric acid level to aim for when treating
gout? Blood uric acid levels are measured in mg/dL.
a. Lower than 10

14 (2.3%)

b. Lower than 8

26 (4.3%)

c. Lower than 6

83 (13.6%)

d. Lower than 2

14 (2.3%)

e. Don’t know

475 (77.6%)

2. What causes gout?
a. Too little calcium
b. Too much uric acid

2 (0.3%)
520 (85.0%)

c. An infection

3 (0.5%)

d. Diabetes

5 (0.8%)

e. Don’t know

82 (13.4%)

3. What causes gout attacks?
a. Infection in the joint

43 (7.0%)

b. Allopurinol in the blood

6 (1.0%)

c. Crystals in the joints

411 (67.2%)

d. Calcium in the blood
e. Don’t know

5 (0.8%)
147 (24.0%)

4. How do you know if you have a gout attack?
a. You have a painful swollen joint

566 (92.5%)

b. You have a change in your blood tests

3 (0.5%)

c. Your skin gets red and itchy

9 (1.5%)

d. You have a lump in your ear

0 (0.0%)

e. Don’t know

34 (5.6%)

5. Lowering your uric acid can help prevent future gout attacks.
Which of these drugs can lower your blood uric acid?
a. Allopurinol

489 (79.9%)

b. NSAIDs like ibuprofen, naproxen and indomethacin

11 (1.8%)

c. Prednisone

9 (1.5%)
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d. Colchicine

34 (5.6%)

e. Don’t know

69 (11.3%)

6. If you are taking a drug to lower your blood uric acid levels, how
long do you need to take this drug?
a. One month

8 (1.3%)

b. One year

5 (0.8%)

c. Two years

5 (0.8%)

d. Forever

380 (62.1%)

e. Don’t know

214 (35.0%)

* Patients were asked to only mark one option per question. Bold answers represent the correct answer.
For the “Primary Attack Symptoms” question, a number of patients recorded multiple symptoms and were
given credit if they included the most accurate answer in bold above. For all other questions, multiple
answers were counted as incorrect. Questions were adapted from a previously published
questionnaire.65,66
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Table 2 Demographics of Questionnaire Responders and Non-responders

Responders

Non-responders

P

(n = 612)

(n = 501)

72.1 (10.7)

72.8 (13.1)

0.36

Male

601 (98.2%)

497 (99.2%)

0.15

Caucasian

536 (89.0%)

-

Married

325 (54.4%)

-

≥ High School Graduate

536 (88.9%)

-

Demographics
Age, years

Baseline Health
BMI, kg/m2
RDCI
GFR, ml/min/1.73 m

2

Age at First Gout Attack, years

32.4 (6.3)

32.0 (6.8)

0.41

2.83 (1.48)

2.97 (1.55)

0.12

65.5 (22.3)

65.5 (25.5)

0.99

51.6 (16.2)

-

Health Behavior
PDC

0.94 [0.77- 0.99]

0.91 [0.67-0.99]

0.005

Rheumatologist Prescriber

42 (6.9%)

10 (2.0%)

<0.001

Received Dose Escalation

206 (33.7%)

155 (30.9%)

0.33

SU test within 1 year

298 (48.7%)

209 (41.7%)

0.02

SU test within 2 years

404 (66.0%)

265 (52.9%)

<0.001

Health Processes of Care

Values in bivariate analysis are frequency (%), mean (± SD) or median [Interquartile range].
Percentages represent analysis in non-missing data. Body mass index (BMI); Rheumatic Disease
Comorbidity Index (RDCI); glomerular filtration rate (GFR); proportion of days covered (PDC); Patient
Activation Measure (PAM); serum urate (SU); Confidence Interval (CI); race/ethnicity, marital status,
education, and age of first gout attack not available for non-responders.
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Table 3 Association of Patient Characteristics with Target Serum Urate Knowledge

Knew SU
goal
(n = 83)

Unadjusted
Did not know
SU goal
(n = 529)

Multivariable Adjusted (n=612)
P

Odds Ratio (95% CI)

P

0.83 (0.70 to 0.98)

0.03

2.1 (1.3 to 3.4)

0.002

Demographics
Age, years

68.7 (10.2)

72.7 (10.6)

<0.001

82 (99%)

519 (98%)

0.66

73 (89%)

463 (89%)

0.99

Married

46 (57%)

279 (54%)

0.64

≥ High school graduate†

75 (93%)

461 (88%)

0.25

BMI, kg/m2

33.1 (5.3)

32.2 (6.4)

0.17

RDCI

2.46 (1.52)

2.88 (1.47)

0.015

GFR, ml/min/1.73 m2

67.8 (23.1)

65.2 (22.1)

0.32

Age at first gout attack

48.6 (16.2)

52.1 (16.2)

0.08

0.92

0.95

0.18

[0.74 - 0.99]

[0.77 - 1.00]

62.1 (11.6)

58.6 (11.3)

0.012

46 (55%)

193 (36%)

0.001

Male
Non-Hispanic Caucasian†
†

Baseline Health

Health Behaviors
PDC

PAM
High Gout Knowledge‡
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Knew SU
goal
(n = 83)

Unadjusted
Did not know
SU goal
(n = 529)

Multivariable Adjusted (n=612)
P

Odds Ratio (95% CI)

P

3.0 (1.4 to 6.2)

0.004

Health Care Process
Rheumatologist Prescriber

12 (14%)

30 (6%)

0.008

Received Dose Escalation

33 (40%)

154 (29%)

0.05

Values in unadjusted analysis are frequency (%), mean (± SD) or median [Interquartile range]. Percentages represent analysis in non-missing
data.
† Variables

were dichotomized for analysis: non-Hispanic Caucasian vs. other, currently married vs. not married and high school graduate vs. less

than high school graduate.
‡ High

Gout Knowledge was defined as answering all 5 of gout-specific questions correctly when excluding the SU goal question. Body mass index

(BMI); Rheumatic Disease Comorbidity Index (RDCI); Glomerular filtration rate (GFR); Proportion of days covered (PDC); Patient Activation
Measure (PAM); Confidence Interval (CI).
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Table 4 Health Outcomes by SU Goal Knowledge

Knew SU goal
(n = 83)
EQ-5D-5L

Did not know SU
goal

P

(n = 529)

0.79 [0.69 to 0.86]

0.78 [0.66 to 0.83]

0.45

Overall Health, 0 to 11

8 [6 to 9]

7 [5 to 8]

0.04

Gout Specific Health, 0 to 11

8 [7 to 9]

8 [6 to 10]

0.72

SU Goal Attainment < 6.0 mg/dl

60 (75%)

319 (71%)

0.44

Gout Attacks in prior 6 months

0.054

0 attacks

39 (49%)

305 (59%)

1 attack

12 (15%)

72 (14%)

> 1 attack

28 (35%)

140 (27%)

*Values are frequency (%) or median [Interquartile range]. Percentages represent analysis in non-missing data.
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2.4 Discussion
This large population of gout patients demonstrated a significant lack of knowledge
about an internationally endorsed treatment target in gout. Only 14% of patients
responded with the correct SU goal of < 6.0 mg/dL and nearly 80% specifically endorsed
a lack of knowledge about their treatment goal. It is now widely accepted that patients
should be actively engaged in decision-making regarding their treatment. International
guidelines specifically recommend patient education on SU goal and the importance of
uric acid as a treatment target.38,49 This study confirms preliminary evidence from a small
questionnaire development study, which showed that only 5 out of 39 U.S. gout patients
at a single rheumatology clinic knew their SU goal.65 The current study is the first to
show this in a large population of gout patients seen by both rheumatologists and nonrheumatologists, including primary care providers.
Patient knowledge of disease and treatment is an important part of a complex array
of psychosocial factors that have been shown to impact health outcomes. While data
supporting the need for specific knowledge is limited, goal setting and goal pursuit are
hypothesized to be integral aspects of persuading and motivating patients to adopt
positive health behaviors.58,59 For example, collaborative goal setting has been
associated with improved outcomes in other chronic health conditions, including
diabetes and hypertension, where treat-to-target approaches have garnered greater
support.74,75 The Chronic Care Model (CCM) suggests that optimal outcomes may be
achieved by knowledgeable patients actively engaged in collaborative care with a
prepared, proactive medical team.9,18,76 In support of this model for gout, a proof-ofconcept study showed that when health care providers educate and engage gout
patients in order to promote positive self-management behaviors, the overwhelming
majority (>90%) achieve SU goal.77 Importantly, patient education specific to SU goal
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attainment as part of a treat-to-target approach was a focus of this successful pilot
intervention. The current study is the first to show that goal setting with patients is not
likely to be a widespread or effectively integrated concept in gout treatment. Even
among gout patients most likely to demonstrate SU goal knowledge, those with 1 or
more attacks in the past 6 months treated initially by a rheumatologist, less than 40%
knew their SU goal.
Prospective studies in hypertension and diabetes have shown that communication
about treatment goals within a collaborative treatment setting is associated with
improved outcomes.74,75 In the current study, SU goal knowledge was independently
associated with an increase in the number of SU measurements during the first 2 years
following ULT initiation. This is important because SU measurement is a prerequisite for
proper ULT dose titration leading to SU goal attainment.38 In other studies, up to 60% of
patients do not receive a SU measurement within the first 2 years of observation
following prescription of ULT.48 Although the analyses were limited by the relatively small
proportion of subjects demonstrating knowledge (n = 83), SU goal knowledge was
associated with slightly better self-reported general health. This same knowledge
demonstrated no association with other distal health outcomes, including health related
quality of life measured using the EQ-5D-5L. There was a trend, albeit not reaching
statistical significance, towards SU goal knowledge being associated with increased gout
flares. This result should be interpreted with caution, however, as neither the direction
nor reasons for this association can be determined. For instance, it is possible that
greater knowledge of gout could lead to increased awareness and reporting of flares.
Alternatively, it is possible that an increased number of flares leads to greater pursuit of
detailed gout-specific knowledge or receipt of a rheumatology referral where their SU
goal may be more likely discussed.
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The results of this study should be taken in the context of the population studied and
its cross-sectional design. The cross-sectional design precluded my ability to determine
causation. The questionnaire design limited my ability to determine the patients’ reasons
for not knowing SU goal, underscoring the potential for this topic as a promising area of
future research. While the majority of the questionnaire required only limited recall, there
is a potential for recall bias with 6-month flares questions. However, self-report is
increasingly accepted as the critical patient-centered outcome in gout. Initial eligibility
was determined by allopurinol receipt during a recent pre-defined 1-year time period.
This led to a high proportion of prevalent allopurinol users relative to incident users.
Furthermore, included patients were by definition willing to respond to a questionnaire.
These two factors likely led to a more engaged and healthy study population as was
evidenced in part by the comparison between questionnaire responders and nonresponders in Table 2. Importantly, this suggests that the estimate of SU goal
knowledge, although quite low, is likely higher than would be seen in a broader patient
population. The study also indicated high levels of medication adherence for both
questionnaire responders and non-responders relative to other recent studies.32,56,78-81
The PDC values in this study are higher than other studies likely due to the high
proportion of prevalent users in the cohort and the use of mailed prescriptions in the VA
system. The mailing service likely reduces barriers to having medication on hand relative
to other systems. While an important consideration, the mailing system does not negate
the relationship of PDC to actual adherence because VA patients are still required to
request a refill each time one is needed. In other words, there is no automatic, timebased refilling system. The primary analysis used a short 6-month allopurinol-free period
of observation before first allopurinol prescription, which may have led to
misclassification due to allopurinol nonadherence. However, a sensitivity analysis using
a 1-year period did not substantially change point estimates.
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In summary, I found that a very low proportion of gout patients receiving ULT know
their treatment goal. This information provides insight into one broadly untapped
pathway to improve the widely reported suboptimal outcomes in gout. More research on
prospective strategies to incorporate SU goal information into efforts in shared-decision
making, quality improvement projects, self-management programs, or educational
materials in gout is needed.

Chapter 3:
Medication Adherence as a Mediator of
Optimal Outcomes in Gout
3.1 Background
Gout has a well-understood etiology for which efficacious, low-cost, and welltolerated treatments are available. Additionally, there is broad international consensus
on best practices among gout management guidelines,38,49,50,62 including achievement of
optimal outcomes through maintenance of serum urate (SU) below a 6.0 mg/dl target.
Recent studies implicate urate lowering therapy (ULT) nonadherence and suboptimal
dosing strategies as major barriers to achieving the SU target.32,47 However, little
progress has been made toward improving gout patients’ outcomes,32,82 and it remains
largely unknown how patient and provider behaviors interact to facilitate achievement of
target SU goals.
Medication adherence to allopurinol among gout patients is widely reported to be low
with only 35-45% considered adherent by pharmacy refill measures.32,56 In a study of
more than 13,000 gout patients initiating allopurinol, representing over 90% of
prescribed ULTs,32 adherence was the single strongest predictor of SU goal
achievement. Among the first studies to report this finding, adherent patients were more
than 2.5-times as likely to achieve SU levels below 6.0 mg/dl compared to nonadherent
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patients. However, associations between adherence and treatment outcomes are
confounded by the “healthy adherer” effect where adherent individuals tend to also be
more actively engaged or “activated” in promoting their health generally.57 Patient
activation is defined as the knowledge, skills and confidence required for patients to be
actively involved in their own care and has been associated with many healthful
behaviors.67,68,83 Importantly, there have been no studies accounting for patient
activation when examining the association of medication adherence with gout outcomes.
In addition to patient factor effects, current prescribing practices likely contribute to
suboptimal outcomes. One of these practices, ULT dose escalation, directly affects SU
goal achievement.32 Importantly, if ULT is initiated, current understanding requires dose
escalation to SU goal for its full therapeutic benefits to be realized.38,49 To maintain a
patient on ULT without appropriately escalating the dose is a case of clinical inertia,
defined as a provider not initiating or intensifying a treatment when indicated.84 Other
provider factors may indirectly affect outcomes by impacting medication adherence. For
instance, gout flares accompanying ULT initiation have been reported as a potential
cause of nonadherence.55,79 These so-called “initiation flares”, however, can be limited
by using low ULT starting doses and appropriate anti-inflammatory prophylaxis.85-87 This
potential causal pathway connecting low ULT starting dose to SU goal attainment
through medication adherence has never, to my knowledge, been studied.
For this study, I adopted the Chronic Care Model (CCM) and chose to focus on
patient and provider factors given the strong evidence of their impact. Specifically, I
examined the association of patient and provider factors with SU goal achievement
among gout patients taking allopurinol. I hypothesized that two patient (medication
adherence and patient activation) and three provider factors (allopurinol dose escalation,
low starting dose and anti-inflammatory prophylaxis) would be associated with SU goal
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attainment. Further, I hypothesized that medication adherence would mediate, at least in
part, associations of other patient and provider factors with SU goal achievement.

3.2 Methods
The design, setting, sample and procedures for this study are described in the
Section 2.2 Methods. Briefly, this cross-sectional study linked patient questionnaire
responses with historical medical and pharmacy dispensing records data from all gout
patients receiving care at a single Midwestern VA medical center to determine patient
and provider factors associated with optimal gout management. The study used the
same inclusion and exclusion criteria for a final cohort of 612 patients (Figure 2)
Primary Outcomes
Laboratory records were used to determine the primary outcome of whether patients
ever achieved SU goal (< 6.0 mg/dl) after allopurinol initiation. Two alternative measures
of goal attainment were used for sensitivity analyses. Recognizing that some patients
may not have a follow-up SU on record, I constructed an alternative measure of SU goal
attainment using the same SU goal (< 6.0 mg/dl), but also classifying patients without a
SU on record as not achieving goal. This reflects expert consensus that follow-up SU
assessments are required for optimal care.38,49 The second alternative used the final SU
value on record to determine goal attainment.
Allopurinol medication adherence was considered as both an outcome and a
predictor variable due to its hypothesized role as a mediator. I was interested in the
implementation component of adherence.88 Specifically, I sought to determine the extent
that a patients’ actual medication taking behavior corresponded to prescribed regimens
once both the provider and patient indicated an intent to establish long-term treatment as
represented by the first allopurinol fill. Allopurinol adherence was determined by
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calculating the proportion of days covered (PDC) during a fixed, 360-day period
beginning on the day of the patient’s first prescription fill. This provided a sufficiently
long, fixed observation period to determine adherence nearest therapy initiation (“early”
adherence). A secondary measure of adherence used in sensitivity analysis was the
PDC calculated during a 360-day period beginning the day of the patient’s first
allopurinol prescription fill after August 1, 2011 (“recent” adherence). Together, the two
measures provided a method for understanding the potential effect of temporal distance
between measures. A PDC ≥ 0.8 was considered adherent and can be intuitively defined
as any patient who was likely to have allopurinol available to use on at least 8 out of
every 10 days observed.32,56,79
Predictor Variables
As noted in Chapter 2, the Patient Activation Measure (PAMTM) was used to quantify
self-perceived knowledge, skills, and confidence needed to manage health.67,68
Importantly, if a patients’ PAM increases over time, their health behaviors improve also
suggesting that activation could be a target for future interventions.89,90 The PAM score
distribution for this study was similar to the mean ± standard deviation (SD) of 56.8 ±
10.0 observed in a large sample of chronic disease patients.91 Importantly, PAM was
correlated with gout-specific knowledge (r = 0.24, p < 0.001) and confidence in gout
treatment plan (r = 0.38, p < 0.001) which were collected in this study to assess PAM’s
convergent validity in gout. Gout-specific knowledge was assessed using the six multiple
choice questions from Chapter 2 (Table 1). Patients’ confidence in their treatment plan
was assessed using the mean score from four 11-cm visual analog scales (VAS) with
anchors from “not at all confident” to “completely confident” that covered the following
topics: 1) discussed medication options to control gout, 2) discussed lifestyle and diet
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options, 3) able to summarize treatment plan and 4) able to do all tasks in treatment
plan.
VA medical and pharmacy refill records were used to determine provider factors in
gout care including allopurinol starting dose, dose escalation and anti-inflammatory
prophylaxis. A low starting dose was defined as ≤ 100 mg/day, consistent with ACR gout
management guidelines.38 Dose escalation was defined as any increase in allopurinol
from the first dose to the final dose.32 Anti-inflammatory prophylaxis was assessed by
determining whether a prescription was filled for non-steroidal anti-inflammatory drugs
(NSAIDs), corticosteroids or colchicine during a window 30 days prior to or within seven
days after the patients’ first ever allopurinol fill on record or if the patients’ days of supply
for anti-inflammatory lasted until after the date of their first ever allopurinol fill.
Other Measures
A number of covariates were collected from the questionnaire including marital status
(married versus not), age at first gout attack, and education level (high school graduate if
patient completed ≥ 12 years of school). To further describe the gout burden in the
cohort and potential need for improvements in health outcomes, I report patients’ selfreported number of gout flares in the past six months.
VA medical and pharmacy dispensing records were used to determine patients’
gender, comorbidity burden, estimated glomerular filtration rate most proximate to
questionnaire completion (GFR, ml/min), body mass index most proximate to
questionnaire completion (BMI, kg/m2), and concomitant medication use. Comorbidity
burden was assessed using ICD-9 codes to determine the patient’s Rheumatic Disease
Comorbidity Index (RDCI) over a 2-year period bracketing the enrollment allopurinol fill
date.71 Concomitant medication use was determined by counting the number of unique
medications filled during a 1-year period beginning August 1, 2011. I used the 25th
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percentile (seven unique medications) as a cut-off for defining high versus low
concomitant medication use. I also identified providers’ primary medical specialty to
account for important practice and patient population differences among specialties.32 To
determine the providers’ primary medical specialty, I used a combination of unique
National Provider Identifier and Drug Enforcement Administration codes. I then assigned
providers’ primary medical specialty according to which clinic code was most often
associated with their prescriptions. For descriptive purposes, medical specialty was
reported in 3 categories (rheumatology, primary care, and other). For analysis, two
categories were used (rheumatology versus other) because the primary care and other
categories performed similarly.
Statistical Analysis
Chi-squared, Fisher’s exact, Wilcoxon rank sum and t tests were used for
comparisons of group characteristics as appropriate. As preliminary analysis for
mediation testing, the association of patient activation and three provider factors
(allopurinol dose escalation, low-dose initiation, and anti-inflammatory prophylaxis) with
medication adherence was examined using multivariable logistic regression. All four prespecified factors were entered into the model and maintained regardless of statistical
significance. Covariates from Table 5 were entered into the model if the univariate pvalue was < 0.20 to ensure important independent variables were not overlooked.
Covariates maintained in the model were identified through a manual backwards
stepwise selection using a p > 0.05 criterion. Interaction terms were considered for the
four patient and provider factors and also removed at p>0.05. A similar process was
used to determine associations with SU goal attainment while including medication
adherence as a patient factor. To determine the optimal combination of five patient and
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provider factors, I used the Akaike Information Criteria (AIC) where the lowest AIC
indicated the best fitting model.
Mediation by medication adherence was tested using a counter-factual approach
with delta-method 95% confidence intervals.92 Specifically, I examined whether
medication adherence mediated the association of the other four pre-specified factors
with achievement of SU goal. Mediation analysis is useful for understanding many types
of potential causal pathways, but it can be especially helpful when a predictor variable X
has a direct association with an outcome Y, but may be inversely associated with the
same outcome through a mediator M.93 A hypothetical example of this “inconsistent
model” would be workers’ ability to make error-free widgets where a worker’s intelligence
(X) is directly associated with fewer errors (Y), but where intelligence also promotes
boredom (M) in turn increasing errors.94 To further illustrate mediation and inconsistent
models, I provide a directed acyclic graph depicting a hypothesized inconsistent model
of mediation proposed in this study (Figure 3).
In sensitivity analyses, I determined whether results substantially changed when
considering whether patients used non-VA pharmacies for any medications, if they
received help taking medications, or had non-VA providers help manage their gout,
obtained through self-report. I considered alternative measures of SU goal attainment
and medication adherence as described above. Given the low frequency of missing
data, complete case analysis was used with the exception of sensitivity analyses where
missing SU goal attainment values were imputed as described under primary outcomes.
Analyses were conducted using SAS v9.4 (SAS Institute, Inc.).
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Figure 3 Conceptual Diagram of an Inconsistent Mediation Model in Gout
Mediation analysis is useful for understanding potential causal pathways. It can be especially helpful for
understanding “inconsistent models” where a predictor variable X has a direct association with an outcome
Y, but may be inversely associated with the same outcome through a mediator M (25). Here I depict an
inconsistent model proposed in this study. A low starting dose (X) is directly associated with a lower odds of
reach serum urate (SU) goal attainment (Y), but a low starting dose also promotes medication adherence
(M) thereby increasing the odds of SU goal attainment.
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3.3 Results
As previously reported in Chapter 2, the questionnaire response rate was 62% (n =
886). The cohort size for the primary analysis, after applying final exclusion criteria, was
612 individuals (Figure 2). Questionnaire responders were similar to non-responders,
except that responders were more likely to receive their first prescription from a
rheumatology office than a primary care or other office, were more adherent to
allopurinol, and were more likely to have their SU checked within the first 2 years after
allopurinol initiation.
The median duration from first allopurinol prescription to questionnaire mailing was
6.0 years (interquartile range 3.2 to 10.3). The prevalence of ever reaching SU goal was
71% (379/531) in patients whose SU was measured following allopurinol initiation and
62% (379/612) when absence of SU measurement during follow-up was considered as a
failure to achieve goal. Forty-nine percent (49%) of patients had their SU checked within
1 year of allopurinol initiation while 66% had SU checked by the end of 2 years. Overall,
43% of gout patients experienced at least one attack in the previous 6 months with a
substantial number (28%) reporting more than one attack during that period. Table 5
displays other patient characteristics.
Associations with Medication Adherence
Considering unadjusted bivariate associations for early adherence (Table 5),
adherent patients (63% of cohort) were slightly older than nonadherent patients (72.8 vs.
70.9 years, p = 0.036), had their first gout attack at an older age (52.7 vs. 49.7 years, p =
0.028), higher BMI (32.8 vs. 31.7 kg/m2, p = 0.033), greater comorbidity (RDCI 2.9 vs.
2.7, p = 0.030), lower activation scores (PAM 58.3 vs. 60.3, p = 0.0497) and were more
likely to receive a low starting dose of allopurinol (36% vs. 27%, p = 0.014). Neither dose
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escalation nor anti-inflammatory prophylaxis were associated with medication
adherence. In sensitivity analysis assessing recent adherence rather than early
adherence, activation and low starting dose were no longer associated with adherence
(data not shown). Early and recent adherence were moderately correlated (r = 0.49, p <
0.001). Other factors reaching the threshold for initial inclusion in the adjusted model
were gender, marital status, loop diuretic use, concomitant medication use, and RDCI.
Of the five patient and provider factors examined in adjusted models, only low starting
dose was associated with higher treatment adherence (OR 1.82, 95% CI 1.20 to 2.76)
(Table 6).
Associations with SU Goal Attainment
Considering unadjusted associations with SU goal attainment, patients at SU goal
had higher activation scores (59.8 vs. 56.2, p = 0.01) and were more likely to be
adherent (76% vs. 66%, p = 0.014) than those not at SU goal. Patients at SU goal were
less likely to receive a low starting dose (27% vs. 48%, p < 0.001). Only 7.5% of all
patients received a final dose over 300 mg/day including only 12 (6%) of the 200
patients who began at a low starting dose. Though not statistically significant, patients
achieving SU goal were more likely to receive allopurinol dose escalation (36% vs. 28%,
p=0.08). Patients achieving SU goal had a higher GFR (68.6 vs. 58.2 ml/min, p < 0.001)
and were more likely to be seen by a rheumatologist (7% vs. 1%, p = 0.036) compared
to patients not achieving SU goal. Loop diuretic use and male gender also reached the
threshold (p < 0.20) for consideration in the adjusted model.
In multivariable analysis, three of the five patient and provider factors were
associated with SU goal attainment while a fourth, patient activation, did not reach
statistical significance, but did improve model performance (AIC 514 with activation vs.
516 without). While both medication adherence (OR 2.35; 95% CI 1.50 to 3.68) and
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dose escalation (OR 2.48; 95% CI 1.45 to 4.25) were strongly associated with SU goal
attainment, low starting dose demonstrated an inverse association (OR 0.21; 95% CI
0.12 to 0.35).
Medication Adherence as a Mediating Factor
In the mediation model, I isolated a positive effect of low starting dose on SU goal
attainment indirectly through early adherence (OR 1.11; 95% CI 1.02 to 1.20) (Table 6).
Isolating this effect maintained the direct, inverse relationship of low starting dose with
SU goal attainment (OR 0.21; 95% CI 0.12 to 0.37). Small effect size increases were
noted for the direct effect of medication adherence and dose escalation in the mediation
model relative to the multivariable logistic regression model.
Sensitivity Analyses
In sensitivity analysis considering recent adherence (Table 7), the association
between low starting dose and adherence was, as expected, attenuated and no longer
significant. The change did not substantially increase the association of adherence with
patient activation, as might have been expected given the shorter temporal distance
between the two after the change. Associations between adherence and provider factors
were also unaffected by the change to recent adherence. Other listed sensitivity
analyses for achieving SU goal are available in Table 8. In general, effect size changes
were modest while the direction and relative effects of the five patient and provider
factors remained largely consistent.
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Table 5 Bivariate Associations with Adherence and Serum Urate Goal Attainment

Overall
n = 612
Age, yrs.

72.1 (10.7)

Adherent

Nonadherent

Serum Urate

Serum Urate

(PDC ≥ 0.8)

(PDC < 0.8)

< 6.0 mg/dL

≥ 6.0 mg/dL

n = 363

n = 229

n = 379

n = 152

72.8 (10.0)

70.9 (11.6)

71.8 (10.4)

72.4 (10.4)
97 †

Male, %

98

98

99

Married, %

54

57

50

54

54

51.6 (16.2)

52.7 (16.5)

49.7 (15.6)

51.0 (15.8)

51.7 (17.0)

32.5 (6.3)

32.8 (6.5)

31.7 (5.8)

32.5 (6.3)

33.1 (6.9)

65.5 (22.3)

65.0 (21.7)

66.3 (23.2)

68.6 (21.8)

58.2 (21.5)

2.8 (1.5)

2.9 (1.5)

2.7 (1.5)

2.8 (1.4)

2.8 (1.5)

89

89

88

89

89

Loop

27

30

22

26

33

Thiazide

22

22

21

21

22

74

77

66

75

72

6.0 [3.2–10.3]

6.2 [3.2–10.4]

5.9 [3.2–10.0]

6.8 [3.5–10.9]

5.1 [2.8–9.8]

Activation Score

59.1 (11.4)

58.3 (11.0)

60.3 (12.0)

59.8 (11.2)

56.9 (12.1)

PDC

0.79 (0.25)

-

-

0.95 [0.81 – 1.00]*

0.92 [0.65 – 0.99]*

63

-

-

76

66

Age at first Attack, yrs.
BMI, kg/m

2

GFR, ml/min
RDCI
High School Graduate, %

99

†

Diuretic Use, %

Concomitant Med Use, %
Duration of Allopurinol Use, yrs

Adherent, %

38

Low Starting Dose, %

33

36

27

27

48

Anti-Inflammatory Proph, %

54

54

55

56

55

Dose Escalation, %

31

30

31

36

28

Rheumatology

5

5

4

7

1

Primary Care

87

88

87

84

92

Other

8

8

8

10

7

Prescriber Specialty, %

All values are %, mean (standard deviation) or median [interquartile range]. Bold values represent statistically significant differences at p < 0.05. † Fischer’s
Exact Test. * Wilcoxon rank sum test. Analysis represents non-missing data. No variable had >3% missing data except age at first attack (6.5%), activation
score (7.5%) and serum urate (13%).

PDC, proportion of days covered; BMI, body mass index; GFR, estimated glomerular filtration rate; RDCI, Rheumatic Disease Comorbidity index
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Table 6 Adjusted Associations of Early Adherence and SU Goal Attainment

Adherent

Serum Urate

(PDC ≥ 0.8)†

< 6.0 mg/dL ‡

Adherence*

Direct Effect*

0.99 [0.98 to 1.01]

1.02 [1.00 to 1.03]

1.00 [1.00 to 1.00]

1.02 [1.00 to 1.04]

-

2.35 [1.50 to 3.68]

-

2.39 [1.51 to 3.78]

Low Starting Dose

1.82 [1.20 to 2.76]

0.21 [0.12 to 0.35]

1.11 [1.02 to 1.20]

0.21 [0.12 to 0.37]

Anti-Inflammatory Proph

0.91 [0.63 to 1.30]

1.07 [0.69 to 1.66]

0.98 [0.93 to 1.05]

1.15 [0.74 to 1.82]

Dose Escalation

0.80 [0.53 to 1.23]

2.48 [1.45 to 4.25]

0.97 [0.89 to 1.04]

2.52 [1.47 to 4.34]

Indirect Effect Via

Patient Factors
Activation Score
Adherent (PDC ≥ 0.8)
Provider Factors

All values represent odds ratio [95% confidence interval]. The 95% confidence intervals for direct and indirect effects were determined
using the delta method. † Model adjusts for age and body mass index. ‡ Model adjusts for estimated glomerular filtration rate and provider
specialty. * Model adjusts for all covariates in early adherence and serum urate goal attainment models listed above. Bold terms represent
significance using 95% confidence intervals. PDC, Proportion of Days Covered; SU, serum urate.
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Table 7 Sensitivity Analysis: Adjusted Associations of Recent Adherence and Serum Urate Goal Attainment

Adherent

Serum Urate

(PDC ≥ 0.8)†

< 6.0 mg/dL ‡

Adherence*

Direct Effect*

1.01 [1.00 to 1.03]

1.02 [1.00 to 1.04]

1.00 [1.00 to 1.00]

1.02 [1.00 to 1.04]

-

2.25 [1.40 to 3.62]

-

2.22 [1.36 to 3.61]

Low Starting Dose

1.38 [0.88 to 2.17]

0.23 [0.14 to 0.38]

1.05 [0.99 to 1.11]

0.22 [0.13 to 0.37]

Anti-Inflammatory Proph

0.88 [0.59 to 1.31]

1.10 [0.71 to 1.70]

0.99 [0.94 to 1.03]

1.17 [0.74 to 1.83]

Dose Escalation

0.65 [0.42 to 1.03]

2.50 [1.46 to 4.27]

0.94 [0.88 to 1.01]

2.52 [1.46 to 4.35]

Indirect Effect Via

Patient Factors
Activation Score
Adherent (PDC ≥ 0.8)
Provider Factors

All values represent odds ratio [95% confidence interval]. The 95% confidence intervals for direct and indirect effects were determined
using the delta method. † Model adjusts for age, body mass index and concomitant medication use (greater than 7 concomitant
medications). ‡ Model adjusts for estimated glomerular filtration rate and provider specialty. * Model adjusts for all covariates in adherent
and serum urate goal attainment models listed above. PDC, Proportion of Days Covered.
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Table 8 Sensitivity Analyses: Adjusted Associations with Early Adherence and Serum Urate Goal Attainment

Excluding Patients

Excluding Patients

Original Serum

Whose Family

with non-VA

Excluding Patients with

Urate Goal

helps with

Providers Involved

any Prescriptions from

Attainment Model

Medications

in Gout Care

Pharmacy other than VA

(n=490)

(n=407)

(n=427)

(n=394)

Activation Score

1.02 [1.00 to 1.03]

1.02 [1.00 to 1.05]

1.02 [1.00 to 1.04]

1.02 [1.00 to 1.05]

Adherent (PDC ≥ 0.8)

2.35 [1.50 to 3.68]

2.23 [1.37 to 3.62]

2.12 [1.32 to 3.41]

2.26 [1.38 to 3.70]

Low Starting Dose

0.21 [0.12 to 0.35]

0.23 [0.13 to 0.41]

0.25 [0.15 to 0.43]

0.22 [0.12 to 0.39]

Anti-Inflammatory Proph

1.07 [0.69 to 1.66]

1.15 [0.71 to 1.86]

0.98 [0.61 to 1.56]

1.10 [0.67 to 1.79]

Dose Escalation

2.48 [1.45 to 4.25]

2.54 [1.41 to 4.57]

1.98 [1.13 to 3.45]

2.36 [1.31 to 4.22]

Patient Factors

Provider Factors

All values represent odds ratio [95% confidence interval]. All models adjust for estimated glomerular filtration rate and provider specialty. PDC,
Proportion of Days Covered.

42

Table 8 Sensitivity Analyses Continued: Adjusted Associations with Early Adherence and Serum Urate Goal Attainment
Using last SU on
Classifying Patients

record & classifying

Original Serum

with no SU

Urate Goal

measurements as not

Using last SU on

Attainment Model*

achieving SU goal

record

(n=490)

(n=562)

(n=490)

goal (n=562)

Activation Score

1.02 [1.00 to 1.03]

1.01 [1.00 to 1.03]

1.00 [0.99 to 1.02]

1.00 [0.99 to 1.02]

Adherent (PDC ≥ 0.8)

2.35 [1.50 to 3.68]

1.88 [1.28 to 2.77]

2.09 [1.40 to 3.10]

1.88 [1.30 to 2.72]

Low Starting Dose

0.21 [0.12 to 0.35]

0.25 [0.15 to 0.39]

0.30 [0.19 to 0.48]

0.31 [0.20 to 0.48]

Anti-Inflammatory Proph

1.07 [0.69 to 1.66]

1.16 [0.80 to 1.70]

1.08 [0.73 to 1.58]

1.13 [0.79 to 1.62]

Dose Escalation

2.48 [1.45 to 4.25]

3.68 [2.24 to 6.05]

2.12 [1.33 to 3.38]

2.92 [1.86 to 4.58]

no SU
measurements as
not achieving SU

Patient Factors

Provider Factors

* This column is repeated to facilitate easy comparison. All values represent odds ratio [95% confidence interval]. All models adjust for estimated
glomerular filtration rate and provider specialty. PDC, Proportion of Days Covered.
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3.4 Discussion
In gout patients treated with allopurinol, medication adherence, dose escalation, and
low starting dose were all strongly associated with SU goal attainment even after
adjustment for patient activation and other relevant covariates. Interestingly, in the
mediation model, low starting dose was indirectly associated with better SU goal
attainment through its positive effect on early adherence while simultaneously being
directly associated with worse SU goal attainment. The positive effect of low starting
dose on medication adherence reflects evidence that smaller decreases in SU level
during treatment initiation are associated with fewer treatment “initiation flares” and
better adherence among patients.55,86 I observed that the direct association with SU goal
attainment was likely driven by the low prevalence of dose escalation observed in this
study. Only about 1 in 3 patients ever received dose escalation of allopurinol, and only
about 1 in 17 initiating allopurinol at a low starting dose ever progressed beyond 300
mg/day, a dose that is insufficient in up to 60% of patients.40 These novel findings
suggest that a strategy of low allopurinol starting dose followed by appropriate dose
escalation to SU goal maximizes goal attainment by promoting both early allopurinol
adherence and long-term lowering of SU.
Contrary to my initial hypothesis, an important and novel finding is the relatively weak
association observed between patient activation and SU goal attainment. Patient
activation is one of the most promising measures currently available for ascertainment of
a patient’s engagement in promoting their health. It is associated with health
maintenance behaviors, such as proper diet, exercise and self-reported medication
adherence,83,89-91 all of which are promoted in gout management guidelines.38,49 In this
study, higher activation scores were associated with higher levels of both gout-specific
knowledge and confidence in treatment plans indicating the PAM measures some level
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of gout-specific engagement. However, this study’s findings suggest that patient
activation may have limited impact on whether or not a gout patient reaches SU goal.
This is consistent with literature showing that health behaviors such as targeted dietary
modifications do not typically bring SU levels below target concentrations.95 Future
studies will be needed to confirm whether or not patient activation is associated
medication adherence as this study appears to be the first to investigate the association
using an objective measure of adherence.
Beyond the novel findings regarding patient activation and mediation by adherence,
results of this study are consistent with other studies of SU goal attainment in
observational settings. The finding of an association between medication adherence and
SU goal attainment (OR 2.35; 95% CI 1.50 to 3.68) is consistent with the OR of 2.52
(95% CI 2.41 to 3.01) observed in the only other study to assess this association.32 My
finding that dose escalation is strongly associated with SU goal attainment is novel, but
consistent with other studies showing increasing odds based on final allopurinol
dose.32,96 I also verified that, in the context of inadequate dose escalation, a low starting
dose of allopurinol is directly associated with failure to reach SU goal.32 Given the
importance of low starting dose in both promoting early adherence and minimizing risk of
allopurinol hypersensitivity reactions,97 overcoming clinical inertia related to dose titration
represents a key target for future interventions.
Anti-inflammatory prophylaxis was not associated with adherence or SU goal
attainment. However, the findings should be considered in the larger context of the
literature. Clinical trial data indicates that anti-inflammatory prophylaxis is effective at
reducing attacks during therapy initiation.85-87 Thus, anti-inflammatory prophylaxis
remains an important best practice in optimal gout management.37
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While care was taken to ensure appropriate relative timing of measures from
electronic records, linkage with questionnaire data makes the study inherently crosssectional precluding causal interpretations. Additionally, the study design promoted a
predominantly prevalent user cohort which in turn likely led to more individuals being
adherent (63%) and achieving SU goal (62-71%) in this study relative to other studies
using electronic health records.32 As I showed, it is important to recognize the ways in
which questionnaire responders differ from non-responders. Notwithstanding this caveat,
the high response rate (62%) and representative distribution of PAM scores gives us
confidence that the estimates of associations are robust within the inherent limitations of
mailed questionnaires.91 Finally, the measure of adherence was based on prescription
refill data, which likely overestimates the number of days medication was taken correctly.
The World Health Organization and others have identified patients and health care
system design as important dimensions for improving medication adherence and patient
outcomes.98,99 Approaches targeting these dimensions would be appropriate for
improving important modifiable factors in this study. Specifically, improved adherence, a
strong predictor of SU goal attainment in this study, among patients with similar diseases
has been achieved by direct-to-patient communication and modifying patient routines.100102

Furthermore, health care system factors, such as clinical decision support or system

redesign efforts, have shown promise in improving prescribing behaviors.103,104 By
implementing these approaches in gout care, we may begin to address the important
barriers to optimal outcomes reported here.
In conclusion, medication adherence and low allopurinol starting dose combined with
appropriate ULT dose escalation represent promising targets for future gout quality
improvement efforts. While targeting patient activation or engagement in personal health
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maintenance may have other important health benefits, this study indicates that such
efforts may have a limited impact on SU goal attainment.

Chapter 4:
Allopurinol Dose Escalation and Mortality
Among Gout Patients
4.1 Background
Hyperuricemia and gout are independently associated with increased
mortality.28,30,31,105 A majority of this increase in mortality risk is thought to be attributable
to excess cardiovascular disease,106 but may also be associated with increased cancer
mortality.107 Multiple studies have shown that hyperuricemia increases interstitial
inflammation and decreases endothelial function, a well-characterized surrogate for
cardiovascular risk.106,108 By contrast, urate lowering therapies (ULTs) such as allopurinol
have been associated with improved endothelial function, reduced blood pressure, and
improved glomerular filtration rate (GFR).109-111 Dubreuil et al. and others have gone
further to show that allopurinol may even lower mortality risk among gout patients.112,113
However, it remains unknown whether a dose relationship exists between ULT and
reductions in mortality.
Allopurinol dosing strategies are a critical point of interest in gout care. Current
guidelines recommend that patients be started on a low dose, ≤ 100 mg daily, and then
titrated up slowly.38 While past randomized clinical trials (RCTs) of ULTs have used
static dosing strategies,40-42 such strategies are suboptimal and should now be
considered unethical. Future studies will likely be required to dose escalate therapy until
patients meet serum urate (SU) goal. This ethical requirement, however, impedes our
ability to understand if ULT dose escalation strategies reduce mortality in gout. Further
limiting are the large sample sizes and lengthy follow-up duration required to determine
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whether appropriate ULT dose escalation favorably impacts mortality and other longterm outcomes. Evidence that these requirements are substantial challenges for study
design and cost can be observed in recent diabetes efforts.114,115
Observational studies of comparative effectiveness can be an important complement
to RCTs especially for definitive long-term outcomes such as mortality.116 It has been
shown that a substantial portion of primary care providers, responsible for approximately
95% of gout management, use a static ULT dosing strategy for gout patients.32 However,
a small but meaningful number of providers use a dose escalation strategy providing a
potential opportunity for comparison. Using a national population of gout patients, I
investigated the effect of ULT dose escalation on mortality. Specifically, I hypothesized
that patients receiving dose escalation would have a lower all-cause and cause-specific
cardiovascular and cancer mortality relative to similar gout patients receiving a static
dosing strategy.

4.2 Methods
Study Setting
I identified a population of gout patients using Veterans Health Administration (VHA)
data from 1999 to 2010. The VHA has provided care for between 5 and 10 million retired
US military enrollees each year since 2001. Data from the VHA’s electronic medical
records and pharmacy prescribing represent longitudinal care provided at 152 medical
centers and 1,400 additional community-based outpatient clinics nationwide. This data,
including demographics, outpatient and inpatient visits, laboratory results, and pharmacy
dispensing, was accessed in the VHA’s Corporate Data Warehouse through the VA
Informatics and Computing Infrastructure (VINCI).117 Many studies indicate the
completeness and validity of various CDW data including gout diagnostic codes.118,119
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Study Population
The target cohort for this study was defined as any gout patient ≥ 40 years old
prescribed incident allopurinol between October 2001 and December 2008. Gout for this
study was defined as having at least 1 International Classification of Disease (ICD-9)
code for gout prior to the incident allopurinol fill with a second ICD-9 code for gout
separated by at least 30 days and occurring prior to the beginning of time at risk
(described below). Also considered to be a first-line ULT,38 febuxostat was approved on
February 2009 and only available to clinical trial participants prior to that date. Patients
were required to have a record of hyperuricemia, defined for this study as SU ≥ 8.0
mg/dl to reflect a gout population most likely to need dose escalation, and at least 1 year
of observability without allopurinol prior to the incident allopurinol date. Observability was
defined as having at least 1 annual VHA primary care or rheumatology visit and filling at
least one prescription every 6 months.120 Patients were excluded if they had an
estimated glomerular filtration rate < 30 ml/min, were involved in a clinical trial for ULT
during observation, or had history of dialysis, organ transplantation, malignancy, or
tumor lysis syndrome.112,113 These exclusions were intended to limit the population of
interest to patients for whom gout was the primary indication for allopurinol receipt. A
total of 31,336 patients met the eligibility criteria for the study and 25,379 of those had
complete data required for propensity score matching as described below (Figure 4).
Mortality Outcomes
The primary outcomes for this study were all-cause and cause-specific
cardiovascular and cancer mortality as defined using the National Death Index (NDI).
The NDI is a centralized database of death record information reflecting state vital
statistic office records and maintained by the Centers for Disease Control and
Prevention. Death records were requested from and matched by VHA staff at the
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Suicide Data Repository which maintains NDI records for VHA. The records include date
of death and cause of death as recorded by ICD-10 codes. Cardiovascular mortality was
defined as any mortality attributed to an ICD-10 code within Chapter IX (I00-I99) and
cancer mortality was defined as an ICD-10 within Chapter II (C00-D48). Competing risks
for cardiovascular and cancer mortality were other causes of mortality and cancer or
cardiovascular mortality, respectively. All-cause mortality was also assessed.
Primary Predictor Variable
Allopurinol dose escalation was the primary predictor variable. Dose escalation was
defined over a 2-year ‘dose escalation’ period which I estimated would encompass
planned dose escalation strategies in practice. Using the dataset in Chapters 2 and 3, I
found that approximately 70% of all allopurinol dose escalation events occurred within 2
years of a new allopurinol prescription. Patients were identified as “dose escalators” if
their final average daily dose within the 2-year period was greater than their initial
average daily dose. Patients were allowed to switch to febuxostat and dose
equivalencies to allopurinol were estimated based on clinic trial data demonstrating that
similar proportions of patients on 300 mg/day of allopurinol and 40 mg/day of febuxostat
reach SU goal (42% vs. 45%, respectively).42 Thus, a patient switching from allopurinol
100 mg daily to febuxostat 40 mg daily was considered to be a dose escalator. For this
analysis, I estimated that the three febuxostat doses observed during follow-up (40, 80
and 120 mg/day) were approximately equivalent to 300, 600 and 900 mg/day of
allopurinol, respectively. Within-prescription dose escalations were accounted for by
review of the medical label instructions (commonly referred to as the medication sig).
Patients having within-prescription dose escalations were categorized as dose
escalators if the final average daily dose of the sig for their last prescription fill during the
dose escalation period was greater than the initial dose from the sig of the incident
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allopurinol fill. To identify dose escalation sigs, unique sigs were reviewed randomly and
iteratively in samples of 200 to detect common characteristics of dose escalation sigs.
Any sigs matching those characteristics were removed for full analysis where each
unique sig was reviewed individually and labeled with the starting average daily dose
and final average daily dose by two reviewers. Any discrepancies were reviewed
together to establish consensus or decided by a third reviewer if no consensus could be
reached. After 2 consecutive random draws found no new common identifiers, 1,000 of
the remaining unreviewed sigs were randomly drawn to estimate the sensitivity of this
identification method. Only 0.5% of the 1,000-sig random sample were identified as dose
escalation sigs translating into an estimated 98% sensitivity for using this method on all
sigs. Because each sig identified for full analysis was individually assessed and verified
by a second reviewer, the specificity is expected to approach 100%.
Propensity Matching
While some differences in whether an individual patient is appropriately dose
escalated may be due to random chance, patients receiving dose escalation may also
systematically differ from those not receiving dose escalation. In order to mitigate
confounding by indication, I used propensity score matching to balance baseline
confounders and prognostic variables between two groups: dose escalators and nonescalators. My methods build on prior work by Dubreuil et al. who designed a propensity
matching approach for allopurinol use among hyperuricemic patients with and without
gout.112 For each patient, I calculated the predicted probability (propensity score) of
receiving dose escalation over the 2-year dose escalation period using a logistic
regression equation. To address time trends in allopurinol use and confounders prior to
matching, patients were sorted into accrual blocks of approximately 6-months in length
from October 2001 to December 2008 (14 blocks) based on the date of the incident
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allopurinol fill. Within each accrual block, I created a matched sample by matching dose
escalators and non-escalators 1:1 based on the logit of the propensity score using
calipers to limit the allowable difference in scores between matches. I used a caliper of
0.2 times the standard deviation of the logit.121 I used a greedy match algorithm such
that, after matching to a dose escalator, non-escalators were removed from the pool of
potential matches.121
The variables used to develop the propensity score estimation were assessed over a
baseline period of up to 2-years prior to the incident allopurinol date. Baseline
characteristics included demographics, body mass index (BMI, kg/m2), comorbidities,
medication use, laboratory values indicating cardiovascular risk, health care utilization
and gout-specific factors. Demographic variables were defined for age at incident
allopurinol date and sex. Comorbidities included hypertension, cardiovascular disease
and diabetes identified by ICD-9 codes. Patients’ comorbidity burden was further
described using the validated Rheumatic Disease Comorbidity Index (RDCI).71
Medication use related to cardiovascular risk was recorded for each of the following
categories: β blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II
receptor blockers (ARBs), calcium channel blockers (CCBs), loop diuretics, thiazides,
statins, fibrates, aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), metformin,
other oral hypoglycemic agents, and insulin. Laboratory values for total cholesterol
(g/dL), albumin (g/dL) and estimated glomerular filtration rate (eGFR, mL/min/1.73 m3
based on serum creatinine using the Modification of Diet in Renal Disease equation)122
were identified using available laboratory data from the date nearest incident allopurinol
during the 2-year baseline period. The total number of primary care visits during this
baseline period was used as a proxy for health care utilization. The number of outpatient
gout diagnoses on record and the presence of an inpatient gout diagnosis as the primary
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discharge diagnosis during the baseline period were used as proxies for gout burden.
Patients were also classified based on presence of a rheumatology visit or consult
during the baseline 2-year period. Finally, the patients’ baseline SU concentration
nearest incident allopurinol date and the index allopurinol dose were included as goutspecific factors.
Assessments for Quality of Care as a Residual Confounder
Propensity matching may not effectively control for confounding if quality of care
concurrent to ULT dose escalation is markedly different between dose escalators and
non-escalators for common comorbidities. For instance, if ULT dose escalators treated
for hypertension tend to have better control of blood pressure than ULT non-escalators,
we may be concerned that unmeasured confounding is biasing estimates. In other
words, it may be that concurrently improving care or healthful behaviors explain some or
all of the association estimated. To assess for this possibility, I report baseline and 2year follow-up values for two process quality variables: percentage of patients with blood
pressure readings ≥ 140 systolic or 90 diastolic mm/Hg among those treated for
hypertension (beta-blockers, calcium channel blockers, thiazides, loop diuretics, ACE
inhibitors or ARBs) and the percentage of patients with a cholesterol > 200 mg/dl among
those treated for hyperlipidemia (statins or fibrates). I also report the percent of patients
with complete observability during the 2-year dose escalation period using the same
aforementioned definition applied to the pre-index period. Patients had to be considered
‘observable’ during both year periods to be considered observable for the 2-year dose
escalation period.
Statistical Analysis
Baseline characteristics of eligible dose escalators and non-escalators were
assessed using standardized differences.123 All listed baseline characteristics (Table 10)
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were used for matching. Balance diagnostics were used to assess the means and
distributions of baseline characteristics of the matched groups. Means of the matched
groups were compared using standardized differences.121 Standardized differences of <
0.1 were considered negligible.121 Continuous variable distributions were compared
using variance ratios, quantile-quantile plots, and non-parametric density plots.124 I
confirmed that all variance ratios fell within F-distribution 95% confidence intervals.124
The plots were visually assessed for deviations in distributions between groups. Nonlinear and interaction terms were subsequently considered if balance diagnostics
indicated that matching did not adequately balance the means or distributions of
baseline characteristics.124,125
Time at risk for both groups began 2 years after the date of incident allopurinol. This
consistent time period between groups eliminates the potential for immortal time to bias
risk estimates.126 For instance, an alternative, but naïve approach may have been to
start time at risk for non-escalators at the time of first allopurinol while waiting for time at
risk to begin for dose escalators until escalation had occurred. Because only living dose
escalators would be included in the study using this method, an ‘immortal’ period before
the escalation event would exist for dose escalators, but not non-escalators. My method
of determining time at risk eliminates the potential that immortal time could bias risk
estimates in favor of the dose escalation group. Competing risks regression and
cumulative incidence plots were used to assess the effect of dose escalation on
cardiovascular and cancer mortality in the presence of other causes of mortality. A Cox
proportional hazards model was used to estimate the effect of dose escalation on allcause mortality with 95% confidence intervals (CI) based on robust variance estimates
to account for matching.125,127
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Figure 4 National Mortality Study Flow Diagram
Any gout patient ≥ 40 years old prescribed incident allopurinol between October 2001 and December 2008
was considered for this study. Gout for this study was defined as having at least 1 International
Classification of Disease (ICD-9) code for gout prior to the incident allopurinol fill with a second gout ICD-9
code separated by at least 30 days and occurring prior to the beginning of time at risk. At total of 111,694
met this inclusion criteria. A total of 78,589 patients were excluded based on one or more exclusion criteria.
Baseline variables were defined for 31,336 eligible patients. Complete data and survival through the dose
escalation were required for matching leading to the final cohort of 23,746 patients for propensity matching.
Out of these, 12,130 (51%) were matched using 1:1 propensity score matching. * The SU and eGFR
exclusions included patients missing 2-year baseline data values: 42,914 and 25,427 patients, respectively.
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4.3 Results
Prior to matching, the 6,931 dose escalators were similar to 16,833 non-escalators
for a majority of the baseline characteristics (Table 9). Only health care utilization
measures and SU exceeded a standardized difference of 0.1. As expected, those
receiving dose escalation had a higher average baseline SU (9.6 mg/dL vs. 9.4 mg/dL),
lower median incident allopurinol dose (100 mg/day vs. 200 mg/day), greater median
number of baseline primary care visits (9 visits vs. 8 visits over 2 years) and were more
likely to have a rheumatologist involved in their care (18% vs. 6% with a rheumatologist
prescribing the baseline allopurinol and 24% vs. 11% with a rheumatology clinic visit
during baseline).
Propensity Matching
Incident allopurinol dates were well distributed over time with the number of eligible
dose escalators and non-escalators during each accrual block ranging from 345 to 724
and 896 to 1,474, respectively. After propensity score matching, all baseline
characteristics were balanced based on standardized differences (all <0.03, Table 9).
Variance ratios and visual inspection of distributions indicated balanced distributions
between groups for all continuous baseline variables. Importantly, 99.8% of patients had
baseline allopurinol doses within 100 mg/d, 76.6% started on the same dose, and those
with higher doses than their match were evenly distributed between dose escalators and
non-escalators (11.7% and 11.8%, respectively). Consistent with a VA gout population,
the mean age was 64 years and over 99% were male.47 The majority of patients had
comorbid hypertension, cardiovascular disease or diabetes; use of medications for these
conditions was common. The propensity matched cohort had similar rheumatology
contact with 11% having their baseline allopurinol prescribed by a rheumatologist and
17% having a rheumatology clinic visit.
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Dose Escalation Practices and Follow-up SU Concentrations
As noted, 99.8% of patients had baseline doses of allopurinol within 100 mg/day of
their matched pair. The median dose increase for dose escalators over the 2-year followup was 100 mg/day with 90% of increases ranging from 50 to 300 mg/day. Only 10% of
patients in the dose escalation group escalated to a final dose greater than 300 mg/day
(Table 11). As expected, dose escalators had greater SU goal attainment during followup (31% vs. 12%). However, even among dose escalators, SU goal was achieved by a
minority of patients.
All-Cause Mortality
There were 2,179 deaths occurred during observation with 1,067 occurring in the
dose escalation group and 1,112 in the non-escalation group. The mortality rates were
48.4 and 46.3 per 1,000 person-years for dose escalators and non-escalators,
respectively. This represents a 4% reduction in mortality risk for dose escalators not
reaching statistical significance (HR 0.96; 95% CI 0.88 to 1.04). Using a cumulative
incidence plot, there is only a negligible difference in mortality incidence over time
(Figure 5).
Cause-Specific Mortality
There were 479 cardiovascular deaths among dose escalators and 490
cardiovascular deaths among non-escalators leading to cardiovascular mortality rates of
20.8 and 21.3 per 1,000 person-years, respectively. For cancer, there were 187 deaths
among dose escalators and 203 deaths among non-escalators translating to cancer
mortality rates 8.1 and 8.8 per 1,000 person-years, respectively. Dose escalation was
not associated with a statistically significant reduction in cardiovascular (HR 0.97; 95%
CI 0.86 to 1.10) or cancer mortality (HR 0.92; 95% CI 0.75 to 1.12). Referring again to
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the cumulative incidence plots (Figure 5), there were only small differences in time to
death between dose escalators and non-escalators after accounting for competing risks.
Assessment for Quality of Care Residual Confounding
Assessments for quality of care were done at baseline and follow-up to determine
whether other factors reflecting quality of care may have changed concurrently with dose
escalation (Table 12). Observability during follow-up was slightly better for dose
escalators relative to non-escalators (94% vs. 91%, standardized difference = 0.1), but
was high overall for both groups. There was no difference in the proportion of patients at
blood pressure goal at baseline or follow-up among those treated for hypertension. At
baseline, cholesterol control was similar for dose escalators and non-escalators. By the
end of follow-up slightly more dose escalators had achieved cholesterol goal than nonescalators, but the standardized difference remained less than 0.1 (80% vs 78%,
standardized difference = 0.06). Overall, these findings indicate minimal differences in
concurrent quality of care indicators between dose escalators and non-escalators.
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Table 9 Baseline Characteristics of Unmatched and Matched Cohorts

Unmatched Cohorts
Dose

Non-

Escalators

Escalators

(n = 6,913)

(n = 16,833)

63.8 ± 10.3

64.4 ± 10.6

99.6

99.7

32.6 ± 6.4

Hypertension, %

Propensity Matched Cohorts
Dose

Non-

Escalators

Escalators

(n = 6,065)

(n = 6,065)

0.05

64.0 ± 10.4

64.0 ± 10.3

0.01

0.02

99.6

99.7

0.01

32.0 ± 6.2

0.09

32.4 ± 6.3

32.4 ± 6.3

0.01

90

89

0.03

90

90

0.02

Cardiovascular Disease,%

50

47

0.06

49

49

<0.01

Diabetes, %

38

35

0.06

37

37

0.01

RDCI, mean

2 [1-3]

2 [1-3]

0.06

2 [1-3]

2 [1-3]

<0.01

Β-blockers, %

60

57

0.07

59

59

<0.01

ACE Inhibitors, %

67

66

0.02

67

67

0.01

ARBs, %

13

12

0.05

13

13

<0.01

CCBs, %

43

41

0.03

42

43

<0.01

Loop Diuretics, %

34

30

0.07

33

33

<0.01

Thiazides, %

51

50

0.02

51

50

0.01

Statins, %

63

61

0.03

63

63

0.01

Fibrates, %

15

13

0.04

14

14

<0.01

Aspirin, %

33

31

0.03

33

32

<0.01

NSAIDs, %

71

70

0.02

71

71

<0.01

Metformin, %

15

15

0.02

15

15

0.01

Other Hypoglycemics, %

23

21

0.03

22

22

0.01

Insulin, %

12

10

0.09

11

11

0.01

9.6 ± 1.6

9.4 ± 1.5

0.18

9.6 ± 1.5

9.6 ± 1.5

0.01

180 ± 44

181 ± 43

0.02

181 ± 44

181 ± 43

<0.01

Baseline Characteristics

Std.
Diff.

Std.
Diff.

Demographics
Age, years
Male, %
BMI, kg/m

2

Comorbidity

Medications

Laboratory Measurements
Serum Urate, mg/dL
Cholesterol, mg/dL
eGFR, mL/min/1.73 m

2

65 ± 21

66 ± 20

0.06

65 ± 21

65 ± 21

<0.01

4.0 ± 0.5

4.0 ± 0.5

0.01

4.0 ± 0.5

4.0 ± 0.5

0.01

100 [100-100]

200 [100-300]

1.09

100 [100-100]

100 [100-100]

<0.01

Primary Care Visits, n

9 [6-14]

8 [6-13]

0.10

6 [9-14]

6 [9-14]

<0.01

Gout Diagnoses, n

Albumin, g/dL
Health Utilization Measures
Incident Allo Dose, mg/d

3 [1-5]

3 [1-5]

0.09

3 [1-5]

3 [2-5]

0.02

Inpatient Gout Diagnosis, %

3

2

0.06

2

2

0.01

Rheumatology Prescriber,%

18

6

0.35

11

11

0.01

Rheumatology Consult, %

24

11

0.34

17

17

0.01
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Baseline characteristics for each group are mean ± SD, percent, or median [interquartile range].
Standardized differences (Std. Diff.) are reported for each baseline variable and values less than 0.1 are
considered negligible. Values are bolded if they are above the 0.1 threshold. Standardized differences are
the preferred statistic for between group comparisons in propensity studies because the statistic is
independent of sample size providing a consistent measure before and after matching. 124 Review of
standardized differences in the far right column for the matched cohort indicate successful matching and
negligible differences in baseline differences between groups.
BMI = body mass index; RDCI = Rheumatic Disease Comorbidity Index; ACE inhibitors = angiotensin
converting enzyme inhibitors; ARBs = angiotensin receptor blockers; CCBs = calcium channel blockers;
NSAIDs = non-steroidal anti-inflammatory drugs (NSAIDs); eGFR = estimated glomerular filtration rate
based on the Modification of Diet in Renal Disease equation; Allo = allopurinol.
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Table 10 Baseline and Follow-up Allopurinol Dosing by Group

Baseline

Follow-up

Non-Escalators

Dose Escalators

Non-Escalators†

Dose Escalators

(n = 6,065)

(n = 6,065)

(n = 6,065)

(n = 6,065)

≤ 100

76%

76%

78%

<1%

> 100 & < 300

19%

19%

18%

38%

300

5%

5%

4%

51%

> 300

<1%

<1%

<1%

10%

Allopurinol Dose*

* Dose represents the average daily dose with allopurinol equivalents used for febuxostat in follow-up calculations.
small proportion of non-escalators (4%) had their dose decreased during the 2-year follow-up.

†

A
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Table 11 Follow-up Serum Urate (SU) by Group

Dose Escalators

Non-Escalators

(n = 6,065)

(n = 6,065)

SU Tested

91%

77%

At SU Goal < 6.0 mg/dL*

31%

12%

6.9 ± 1.9

7.6 ± 1.7

Follow-up SU, mean mg/dL

Values are percentages and mean ± SD. Only the last value on record for follow-up
was used if there were multiple. * Calculation includes those missing SU tests.
Among only those with follow-up testing 34% of dose escalators and 16% of nonescalators were at SU goal.
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Figure 5 Time to Death for Propensity Matched Dose Escalators and Non-escalators
The cumulative incidence of (A) all-cause mortality, (B) cardiovascular mortality, (C) cancer mortality during
follow-up. In all graphs, dose escalators are represented by the solid line and non-escalators by the dashed
line.
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Table 12 Assessment of Quality of Care as a Residual Confounder

Baseline

Follow-up

Dose

Non-

Dose

Non-

Escalators

Escalators

Escalators

Escalators

Observability*

100%

100%

94%

91%

BP < 140/90 mmHg

63%

63%

68%

68%

Cholesterol < 200 mg/dL

72%

71%

80%

78%

* Observability at baseline was defined for a 1-year period, but was defined for the full 2-year dose
escalation period for follow-up. A patient was considered observable for the period if they were observable
for both 1-year periods. All lab values are the last on record during the 2-year follow-up if more than one was
available.
BP = blood pressure
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4.4 Discussion
In this study, there was no evidence that current dose escalation practices reduce
mortality risk, all-cause or cause-specific. ULT dose escalation produced a statistically
insignificant 4% reduction in all-cause mortality risk as well as non-significant 3% and
8% reductions in cause-specific mortality of cardiovascular and cancer etiology,
respectively. The lack of statistical significance was despite this being the largest study
to date of ULT treatment effects on gout patient mortality.112,113,128 However, I also
showed that patients receiving ULT dose escalation were not dose escalated to a level
typically required for proper gout control.38,39 Such clinical inertia, especially among
those receiving dose escalation, limited my ability to determine the effect of appropriate
dose escalation on mortality. These results add to the persistent uncertainty regarding
the role of ULT in reducing mortality risk.107,129
This study has a number of design strengths that further inform our understanding of
ULT and mortality risks. First, I successfully linked a large national cohort of gout
patients to cause-specific mortality data. Previous studies have typically reported allcause mortality thus limiting understanding about the relative impact of therapy on
causes of mortality such as cardiovascular disease or cancer.112,113 While most studies
have focused on the potential cardiovascular benefits of ULTs that may lead to reduced
mortality,129 there is a potential that reducing hyperuricemia may also have effects on
cancer mortality.107 While neither were statistically significant in this study, the point
estimate for reductions in cancer mortality was stronger than reductions for
cardiovascular mortality. Few conclusions should be drawn from these findings other
than to emphasize that until a more definitive link is determined, assertions regarding
cause-specific cardiovascular mortality reductions from all-cause mortality data are likely
pre-mature.
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This study employs a new-user, active-comparator design novel among studies of
ULT treatment associations with mortality among gout and hyperuricemic patients. This
approach is particularly robust as it better reflects treatment decisions and treatment
recommendations for gout and hyperuricemia than study designs using comparisons
against non-initiator groups (patient never treated with allopurinol). Comparing to
patients not initiated on therapy is likely a comparison against a heterogeneous group. 130
Specifically, not all gout patients are recommended for ULT, such as those experiencing
infrequent gout attacks and lacking tophi or evidence of gout-related joint damage.38,49
Additionally, patients with asymptomatic hyperuricemia are not recommended for ULT
initiation.38,49 These two groups comprise a low-risk subpopulation of non-initiators. The
non-initiator group likely also contains a high-risk population of patients, potentially near
death, for whom prescribers are less likely to initiate a new medication.130 Studies in
other diseases have termed this the risk-treatment mismatch or paradox.131,132 This
study mitigates this potential bias by comparing two groups both initiating ULT therapy.
The similarity of the dose escalator and non-escalator groups is reflected in the
unmatched baseline characteristic comparisons in Table 9. This study further balanced
residual differences between groups through a rigorous propensity score
method.124,125,133 Together, these methods likely led to a less biased estimate of
treatment effect.
Here and elsewhere, I have demonstrated that clinical inertia, or the lack of
increasing treatment intensity when indicated,84 is common in gout management even
among those receiving initial dose escalation.32 In this study, only 30% of dose
escalation patients completed the 2-year follow-up period at SU goal. It is possible that
the clinical inertia observed in this study greatly limited my ability to determine ULT dose
effects on mortality risk reduction. The potential that such under-dosing limited my
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findings is consistent with at least one study showing that increases in forearm blood
flow, a measure of endothelial function, were significantly greater for patients
randomized to 600 mg/day allopurinol doses than for those assigned to 300 mg/day or a
placebo.111 Additionally, if the mortality reduction hypothesized to be attributable to ULT
is associated with reductions in cumulative systemic inflammation from gout attacks,134
then dosing practices reported in this study are unlikely to decrease such inflammation.
International guidelines, supported by evidence-based studies, recognize that dose
escalation until SU is below 6.0 mg/dL is typically required for long-term reduction in
gout attacks.38,49 Without SU goal achievement, allopurinol initiation may only serve to
transiently increase systemic inflammation associated with treatment initiation attacks
while not serving to significantly reduce long-term attack risk.85-87
In the place of ULT dose escalation, I could have considered the effect of SU goal
attainment or SU change on mortality risk similar to a recent study.128 That approach
would have directly investigated one of the hypothesized causal links, SU concentration,
between ULT and mortality reduction.107,129 However, I chose to focus on dose
escalation for a number of reasons. First, the approach frames the issue as an RCT
would by comparing the effect of treatment strategies. Second, investigating dose effects
more broadly reflects the many hypothesized mechanisms through which allopurinol or
febuxostat may reduce mortality. Specifically, studies indicate that allopurinol may
improve endothelial function through its inhibition of xanthine oxidase and corresponding
reduction in reactive oxygen species rather than its urate lowering effect.111,129 Third,
there exists a significant deficit in periodic SU evaluation among observational cohorts
creating a potentially insurmountable missing data problem. Specifically, estimates of
follow-up SU testing range from 15-30% at 6 months to 50% at 4 years.48 Such
infrequent testing and likely baseline differences between those with follow-up SU
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testing versus those without would have made even the best imputation techniques
inadequate. Thus, my decision to investigate dosing strategies reflects my belief that it
better reflects provider treatment choices, the totality of hypothesized causal effects, and
the limitations of available data.
Despite the many strengths of this study, interpretation must account for its
limitations. As previously noted, my ability to fully understand the dose effects of ULT
was limited by the clinical inertia observed in practice. This study is observational in
nature. While the new-user, active-comparator design and use of propensity matching
likely mitigated potential confounding by many measured and unmeasured risk factors, I
cannot eliminate the potential for residual unmeasured confounding. To specifically
address gout severity as a residual unmeasured confounder, I included baseline SU
level, rheumatologist care and number gout diagnostic codes on record as proxies for
severity. While these methods were improvements over past studies, current medical
records are limited in their ability to determine gout severity with no validated and
systematically documented measures that would fulfill this need. Finally, the population
largely reflects the patient population typically being treated with ULT for gout. However,
females comprised less than 1% of the population limiting external validity of the results
for females.
In conclusion, I found no association between ULT dose escalation and reduced
mortality. The findings were likely limited by suboptimal ULT dosing observed in practice
even among dose escalators. While I hoped that this study would add to the evidence
that appropriate dose escalation has significant benefits for gout patients, clinical inertia
during appropriate dose escalation is so prevalent that I cannot make a definitive
assessment. Interventions to overcome clinical inertia in ULT dose escalation may be
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needed before understanding about dose effects can be made, including the potential
benefits for mortality.

Chapter 5:

Discussion

5.1 Summary
Gout is the most common form of inflammatory arthritis, but it is also considered one
of the most treatable. In this dissertation, I have applied the patient and provider portion
of the Chronic Care Model (CCM) framework to draw further insight into modifiable
barriers to optimal outcomes in gout. Importantly, this work builds on prior studies that
identified deficits related to quality indicators, safe prescribing or patient adherence to
therapy by assessing their association with optimal outcomes in an observational setting.
These findings build a foundation for future work to target important modifiable factors
identified here.
Patients’ engagement in their own care is increasingly recognized as a critical
pathway toward improved outcomes.14 In this dissertation, I demonstrated that gout
patients may have a deficit in treatment goal knowledge relative to other knowledge
about gout. Only 14% of patients knew their serum urate (SU) goal. Yet, over 70%
answered at least 4 out of the other 5 gout knowledge questions correctly indicating an
otherwise good understanding of their disease. This discrepancy between knowledge of
gout as a disease and knowledge of a critical treatment goal raises the potential that
goal setting is underutilized in gout care. Literature on goal setting in health suggests
that it may be an important aspect of obtaining optimal outcomes for chronic
diseases.59,74,75 More broadly, knowledge of goals and goal-setting processes are
highlighted in numerous behavior change and theoretical models including CCM.10,11,58
In the following section, I identify initiatives where SU goal is currently being promoted
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and demonstrate the many ways that a goal-setting framework can be incorporated into
comprehensive approaches to CCM-based improvement initiatives.
Recently, more emphasis has been placed on a collaborative patient-provider
approach to achieving optimal outcomes in chronic disease.59,76,135 In this dissertation, I
demonstrated that current practices in gout management may benefit from greater use
of a collaborative approach. Specifically, both patients’ adherence to urate lowering
therapy (ULT) and providers’ dosing practices were strongly associated with SU goal
attainment. For provider dosing practices, dose escalation and high starting dose were
significantly associated with SU goal attainment, but high starting dose was also
associated with worse SU goal attainment through its negative effects on ULT
adherence. The effect of a provider’s choice for starting ULT dose on patient’s ULT
adherence illustrates a specific area of potential impact for a more collaborative
approach. If providers start on lower ULT doses and work with patients to overcome
initiation attacks and other challenges that arise when starting a new ULT, patients
would likely achieve better outcomes. Demonstration of the interrelation between patient
and provider behaviors is not limited to my findings. In diabetes, studies show that low
patient medication adherence is associated with clinical inertia in potentially appropriate
treatment intensification.136,137 This is a potentially intuitive finding. Providers may
recognize that some patients are nonadherent creating uncertainty regarding the
appropriateness of treatment intensification. Thus, if patients remain nonadherent, then
interventions focusing strictly on dose escalation practices may be incongruent with the
realities of practice and thus fail to impact outcomes. The interrelated nature of patient
and provider behaviors increases the need for multi-faceted interventions. I explore
potential components of multifaceted approaches in the following section on future work.

70

The difficulty of demonstrating associations of certain modifiable patient and provider
behaviors with long-term outcomes has been a major barrier in developing an evidencebased approach to improving patient outcomes in practice.138 In Chapter 4, I developed
a promising and methodologically rigorous approach to understanding the effect of ULT
dose escalation on mortality outcomes in gout. I used a new-user, active-comparator
design and propensity score matching approach to investigate whether a ULT dose
escalation strategy was associated with decreased mortality relative to a static dose
strategy. While I found no difference in mortality outcomes between the two dosing
strategies, conclusions were limited due to pervasive clinical inertia even among dose
escalators. With only 30% of patients achieving SU goal and only 10% being escalated
above 300 mg/day of allopurinol, I was forced to conclude that current dose escalation
efforts are insufficient to determine the effect of appropriate dose escalation. While
limiting for understanding associations of ULT with mortality outcomes in gout, the
findings further emphasize the importance of developing methods to target patient and
provider factors identified in this dissertation as important for achieving SU goal.

5.2 Future Work
Chronic diseases are likely to remain a primary driver of health care utilization for the
foreseeable future. For this reason, methods for improving patient outcomes in chronic
disease will need to evolve to address the ever growing demand. Often, the quick and
easy solution suggested by researchers who identify gaps in quality of care is to provide
more education to patients and providers, but decades of research indicate that such an
approach has limited effectiveness.58,139,140 Knowledge, alone, is not sufficient. Instead,
there is convergence from research in a number of fields, including treatment
adherence,141 clinical decision support,142 and dissemination and implementation
research138 indicating that successful interventions are most often multi-level (e.g. target
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individuals, systems and/or organizations) and multi-faceted (e.g. use two or more
methods flexibly for accomplishing the same outcome). The CCM, supplemented by
other work, provides a foundation for developing multi-level, multi-faceted approaches
for improving quality and patient outcomes in gout care.
First, there is a critical need for development of clinical information systems that
better reflect the diagnostic process, shared-decision making, clinical context, and
uncertainty. For the studies reported here, I used a common medical coding system and
medication prescribing to identify gout patients for whom treatment was initiated. This
approach is commonly used in health services research and beyond, but it has
limitations. Medical coding, developed primarily for billing purposes, does not equate to
disease presence. For this reason, there are efforts to develop ‘computable phenotypes’
for diseases with the idea that differing combinations of diagnostic codes, timing of
codes, and other factors can improve the sensitivity and specificity for disease
identification.143 Well-documented and validated computable phenotypes will improve
identification, but still lack the functional meaning that would facilitate improvements in
quality of care. Efforts to improve care based on electronic health records would benefit
from greater detail about the goal of treatment or lack of treatment to guide
understanding of expected outcomes. This information could even incorporate shareddecision making, or the process of patients and providers reviewing evidence to
collaboratively determine the best course of action for a particular patient.144 For
instance, in gout there is little debate that health care providers should suggest longterm ULT for patients severely affected by gout, but for patients with infrequent attacks
who do not want to take a daily medication there is uncertainty about the benefits of
long-term therapy. 38 Shared-decision making may be particularly useful in cases where
uncertainty is highest. Similarly, the A1c treatment goal for diabetic patients can vary
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depending on their risk for developing dangerous hypoglycemic episodes creating
uncertainty in the optimal goal.145 Clinical information systems should be able to reflect
therapeutic goals that develop over time and respond to patients’ changing conditions.
Understanding the goal of treatment and the input of patients could deepen
understanding of quality beyond the one-size-fits-all approach often imposed in research
studies due to current record-keeping limitations. Indeed, some suggest that evidencebased medicine loses significance without inclusion of patient preferences.142,144 Until
clinical information systems better track varied circumstances of treatment and goals,
our ability to understand quality using these systems will be limited to sometimes overly
generalized assumptions.
Clinical decision support is an approach addressed by CCM that has enormous
potential to assist health care providers in overcoming barriers to outcomes identified in
this dissertation. Clinical decision support relies on the idea that a health care provider
working in partnership with a well-designed, user-centered information resource will
perform better than a provider on their own.146 A potential approach in gout and other
chronic diseases would be to create disease dashboards147,148 that would simultaneously
allow the provider to review a patient’s disease-specific history and nudge them to make
decisions consistent with the patient and current evidence-based recommendations. For
instance, a gout dashboard could display a patient’s history of gout attacks, a graph of
their historical SU levels with relevant ULT doses, and one-click ordering for SU testing
or ULT. The system could even nudge providers by making the default option for ULT a
dose escalation if the patient is below SU goal or a reorder (static dose) if the patient is
at SU goal. Since chart review is where providers spend a large share of their time when
using electronic health records,149 convenient organization of disease information and
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ordering could simultaneously improve efficiency and help overcome clinical inertia in
dosing practices.
Another opportunity identified by CCM is delivery system design. Bodenheimer and
colleagues suggest that the ‘tyranny of the urgent’ during clinic visits overwhelms the
periodic steps required for optimal chronic disease management.14 A potential method of
addressing this is to allow the primary health care provider to initiate treatment strategies
that are efficiently operationalized by a health care team and potentially facilitated by
technology. Interestingly, this approach is currently being studied as part of a pragmatic
randomized trial for gout treatment within a large integrated health system.150 In the trial,
gout patients are identified through electronic medical records shortly after initiating
allopurinol. An ambulatory care pharmacist and an automated calling system are then
used to provide protocolized care promoting SU goal attainment. Consistent with
findings in this dissertation, the protocol emphasizes improving medication adherence
among patients who report poor ULT adherence and then dose escalating patients who
fail to achieve SU goal despite being adherent. This is but one approach to system
redesign that could improve outcomes by separating the predictable sequences of care
required to achieve optimal chronic disease outcomes from the primary care provider’s
important role in identifying disease, initiating therapy strategies, and addressing critical
issues that arise overtime in care.
The CCM suggests that for chronic conditions, self-management support should
involve “collaboratively helping patients and their families acquire skills and confidence
to manage their chronic illness, providing self-management tools…, and routinely
assessing problems and accomplishments.”14 The level of self-management support
changes in direct proportion to the pervasiveness of the disease and treatment impact
on the patient’s day-to-day life. For instance, intensive self-management programs were
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developed for rheumatoid arthritis patients during the 1990’s when the disease was often
crippling despite therapy.15 Fortunately for most gout patients, self-management is
limited to eating a good diet, exercising, and properly using medications. However, as I
demonstrated in Chapter 2, even these self-management activities can pose substantial
challenges. When a patient is initiated on ULT, they may experience initiation attacks
causing them to discontinue therapy without notifying their health care provider.
Appropriate response to gout attacks is a critical self-management skill for gout patients
that may not be required for months after first learning from the doctor what to do, if they
are informed at all. In addition to the finding that patients may be inappropriately
discontinuing therapy, one study suggests that patients who visit their health care
provider during an attack may actually be more likely to use therapy inappropriately
following their visit.151 Recognizing the limitations of early in-office patient education,
these findings suggest that direct-to-patient resources providing timely and patientcentered information may have a role in optimizing self-management. For instance, a
smartphone app could allow patients to review long-term management152 and also push
time-sensitive information to patients. In gout, patients could be given access to track
progress toward SU goal over time, which may provide the conceptual link between their
medication use and health that is necessary to promote adherence. Beyond tracking
treatment progress, smart phones could use predictive analytics to identify when a
patient is likely to be having a gout attack and provide the patient with in-the-moment
instructions for medication use. These approaches represent important opportunities to
develop better self-management among patients and could translate into improved longterm outcomes.
In addition to the above 4 areas, CCM identifies two broader areas where targeted
efforts may improve outcomes: community resources and policies and health care
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organization. Communities can significantly impact patients’ chronic disease outcomes
through the availability of healthful food,153 safe outdoor exercise areas,154 and social
support groups.155,156 In gout, community norms surrounding each of these has the
potential to reduce the number of people developing gout as well as reducing
consumption of common triggers of gout attacks (e.g. purine-rich meats, high-fructose
drinks, and beer).157 In addition to communities, the organization of health care can have
an outsized impact on chronic disease outcomes.158-160 For instance, government and
health care businesses can promote or discourage certain care practices through
incentives.161,162 It is now widely recognized that the US health care system payment
structure primarily incentivizes the volume of health care, such as the number of short
clinic visits and procedures, more heavily than quality which may require more time
dedicated to care follow-up and behavioral change approaches.163 More recently, efforts
have been aimed at altering incentives to better reflect the type of chronic care that
patients like those with gout require. For instance, payment models are being developed
that may make it more financially feasible to use clinic time to coordinate chronic
care.164,165 While the community and health care organization elements of the CCM are
sometimes more difficult to target in research, their effects can be far reaching and
should not be over looked.

5.3 Conclusion
Improving patient outcomes in chronic disease is of critical importance to the future
of health care. Gout, affecting 4% of the US population, is a highly treatable chronic
disease from which patients experience unnecessarily suboptimal outcomes. In this
dissertation, I demonstrate how interrelated patient and provider factors affect patient
outcomes in gout. Importantly, the factors, including low knowledge of SU goal, low
patient ULT adherence and suboptimal ULT dosing practices by providers, are all readily
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modifiable. Historically, efforts to improve patient and provider behaviors have focused
on education and outreach, but future interventions will likely find greater success
addressing the broad care context outlined in the CCM to target these interrelated,
modifiable factors and achieve optimal outcomes in gout.
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Dissertation Appendix A: Questionnaire

Gout Quality Improvement Project
Department of Veterans Affairs Nebraska-Western Iowa Health Care System
Date you completed this questionnaire:

/

/
(mm/dd/yyyy)

Please do NOT write your name or identifying information on this questionnaire.
By filling out this questionnaire, you are consenting to be in the study and have
your medical records reviewed.

Instructions
1. You will need a blue or black pen that won't bleed through the paper.
Please do not use pencil or red ink.

Yes

No

These squares should be marked with an X like this:

Yes

2 . You will see a lot of small squares like this:

No

Be sure to make your X inside the box, and fairly heavy, so the computer can read it.

3. You will also see some scales like the one below. You will need to make a mark in the box that
best corresponds to your answer. These scales are usually 0-10. Read carefully to determine what
the question is asking. In this example, the box marked with an X represents a person having a
great deal of pain.
0
10
NO PAIN

SEVERE PAIN

FOR OFFICE USE ONLY
10000000

27421

Background
The following questions are meant to gather background information about you.
1. How old were you when you had your first gout attack?

years old

2. Does someone else, such as a family member, help you take your medications?
3. Do any non-VA, private providers manage your gout?

Yes

Yes

No

No

4. Do you receive any prescription medications from a pharmacy other than
the VA pharmacy?
Yes
No

Treatment Plan
The following are questions about the treatment plan you and your doctor have decided on
for your gout. For each question, please place an x on the 0-10 scale to show how
confident you are.
1. How confident are you that you and your doctor have discussed the medication options available
to control your gout?
Not at all
confident

10

0

Completely
confident

2. How confident are you that you and your doctor have discussed lifestyle and diet changes that may
help control your gout?
Not at all
confident

10

0

Completely
confident

3. How confident are you that you could summarize the treatment plan you and your doctor have chosen
to control your gout?
Not at all
confident

10

0

Completely
confident

4. How confident are you that you can do all the tasks in the treatment plan?
Not at all
confident

10

0

10000000

Completely
confident

27421
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Personal Views about Health
Below are statements that people sometimes make when they talk about their health. Place an X in a box
to the right of each statement according to how much you agree or disagree with it. When answering
please consider your health generally. Your answers should be true for you and not just what you think
others want you to say.
If the statement does not apply to you,
place an X in the box for N/A.

Strongly
Disagree

Disagree Agree

Strongly
Agree

1. When all is said and done, I am the person who is
responsible for taking care of my health.
2. Taking an active role in my own health care is the most
important thing that affects my health.
3. I am confident I can help prevent or reduce problems
associated with my health.
4. I know what each of my prescribed medications do.
5. I am confident that I can tell whether I need to go to the
doctor or whether I can take care of a health problem myself.
6. I am confident that I can tell a doctor concerns I have even
when he or she does not ask.
7. I am confident that I can follow through on medical
treatments I may need to do at home.
8. I understand my health problems and what causes them.
9. I know what treatments are available for my health problems.
10. I have been able to maintain (keep up with) lifestyle
changes, like eating right or exercising.
11. I know how to prevent problems with my health.
12. I am confident I can figure out solutions when new
problems arise with my health.
13. I am confident that I can maintain lifestyle changes,
like eating right and exercising, even during times of stress.
10000000
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N/A

Medications
The following questions ask for your views about anti-gout medication. Please place an X in the
box to show how much you agree or disagree with each of the following statements.
1. My anti-gout medication works for me.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree

Agree

Strongly agree

Agree

Strongly agree

2. My anti-gout medication makes me feel worse.
Strongly disagree

Disagree

Neutral

Over the past 7 days:
1. I took all doses of my anti-gout medication.
Strongly disagree

Disagree

Neutral

2. I missed or skipped at least one dose of my anti-gout medication.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree

Agree

Strongly agree

3. I was not able to take all of my anti-gout medication.
Strongly disagree

Disagree

Neutral

Health
The following questions ask you to share your views about your health and how gout
affects it.
Place an X in the box that best describes how you are doing.
1. Considering your HEALTH OVERALL, rate how you are doing on the following scale.
VERY
POOR

10

0

VERY
WELL

2. Considering ALL THE WAYS THAT GOUT AFFECTS YOU, rate how you are doing on the
following scale.
VERY
POOR

10

0

VERY
WELL

3. How many acute gouty arthritis flares or attacks have you had in the past 6 months?
0

1

2

10000000

3

4

5

more than 6
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Health, continued
For each question below, place an X in the one box that best describes your overall health today.

MOBILITY

I have no problems walking
I have slight problems walking
I have moderate problems walking
I have severe problems walking
I am unable to walk
ANXIETY/DEPRESSION

I am not anxious or depressed
I am slightly anxious or depressed
I am moderately anxious or depressed
I am severely anxious or depressed
I am extremely anxious or depressed
PAIN/DISCOMFORT

I have no pain or discomfort
I have slight pain or discomfort
I have moderate pain or discomfort
I have severe pain or discomfort
I have extreme pain or discomfort
USUAL ACTIVITIES (e.g. work, cooking,
housework, family or leisure activities)

I have no problems doing my usual activities
I have slight problems doing my usual activities
I have moderate problems doing my usual activities
I have severe problems doing my usual activities
I am unable to do my usual activities
SELF-CARE

I have no problems washing or dressing myself
I have slight problems washing or dressing myself
I have moderate problems washing or dressing myself
I have severe problems washing or dressing myself
I am unable to wash or dress myself

10000000
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Gout Knowledge
The following questions ask you to share what you know about gout. Since we are hoping to determine
if certain knowledge is useful for you, it is important that you answer these questions without any help.
Please select only 1 answer for each question.
1. What causes gout?
Too little calcium

Too much uric acid

2. What causes gout attacks?

An infection

Diabetes

Infection in the joint

Allopurinol in the blood

Crystals in the joint

Calcium in the blood

Don't know

Don't know

3. How do you know if you have a gout attack?
You have a painful swollen joint
Your skin gets red and itchy

You have a change in your blood tests
You have a lump on your ear

Don't know

4. Lowering your uric acid can help prevent future gout attacks. Which of these drugs can lower your
blood uric acid?
Allopurinol

NSAIDs like ibuprofen, naproxen and indomethacin

Prednisone

Colchicine

Don't know

5. What is the ideal blood uric acid level to aim for when treating gout?
Blood uric acid levels are measured in mg/dL.
Lower than 10

Lower than 8

Lower than 6

Lower than 2

Don't know

6. If you are taking a drug to lower your blood uric acid levels, how long do you need to take this drug?
One month

One year

Two years

Forever

Don't know

1. How many years of school have you completed? Please X the box to the left of the number
of years of school you have had.
1
2
3
4
5
6
7
8
- - - - - - - - - - - -Grade School - - - - - - - - - - - -- - -

9
10
11
12
- - - -High School- - - - -

13
14
15
16
17+
- - - - - - -College- - - - - - - - - - - - ------

2. Please tell us your ethnic background:
White, not of hispanic origin
Black, not of hispanic origin
3. Current marital
status? (check one)

Asian or Pacific Islander
Hispanic

Never married
Married

Separated
Divorced

American Indian or Alaska Native
Other

Widowed
Remarried after divorce
Remarried after death of spouse

Thank you for completing the survey. Please place it into the envelope provided and return
it by US mail. The envelope has already been addressed and stamped for return so there is
no cost for you!
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